<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92731</article-id><article-id pub-id-type="doi">10.7554/eLife.92731</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92731.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Depletion of SMN protein in mesenchymal progenitors impairs the development of bone and neuromuscular junction in spinal muscular atrophy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-331566"><name><surname>Hann</surname><given-names>Sang-Hyeon</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0871-3414</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-335787"><name><surname>Kim</surname><given-names>Seon-Yong</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-335788"><name><surname>Kim</surname><given-names>Ye Lynne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-335789"><name><surname>Jo</surname><given-names>Young-Woo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-335790"><name><surname>Kang</surname><given-names>Jong-Seol</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-335791"><name><surname>Park</surname><given-names>Hyerim</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-23886"><name><surname>Choi</surname><given-names>Se-Young</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7534-5167</contrib-id><email>sychoi@snu.ac.kr</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-63174"><name><surname>Kong</surname><given-names>Young-Yun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7335-3729</contrib-id><email>ykong@snu.ac.kr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>School of Biological Sciences, Seoul National University</institution></institution-wrap><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Department of Physiology, Dental Research Institute, Seoul National University School of Dentistry</institution></institution-wrap><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ryu</surname><given-names>Vitaly</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Behrens</surname><given-names>Timothy E</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>06</day><month>02</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP92731</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-09-21"><day>21</day><month>09</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-10-10"><day>10</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.06.561282"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-07"><day>07</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92731.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-01-23"><day>23</day><month>01</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92731.2"/></event></pub-history><permissions><copyright-statement>© 2023, Hann, Kim et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Hann, Kim et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92731-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-92731-figures-v1.pdf"/><abstract><p>Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by the deficiency of the survival motor neuron (SMN) protein, which leads to motor neuron dysfunction and muscle atrophy. In addition to the requirement for SMN in motor neurons, recent studies suggest that SMN deficiency in peripheral tissues plays a key role in the pathogenesis of SMA. Using limb mesenchymal progenitor cell (MPC)-specific SMN-depleted mouse models, we reveal that SMN reduction in limb MPCs causes defects in the development of bone and neuromuscular junction (NMJ). Specifically, these mice exhibited impaired growth plate homeostasis and reduced insulin-like growth factor (IGF) signaling from chondrocytes, rather than from the liver. Furthermore, the reduction of SMN in fibro-adipogenic progenitors (FAPs) resulted in abnormal NMJ maturation, altered release of neurotransmitters, and NMJ morphological defects. Transplantation of healthy FAPs rescued the morphological deterioration. Our findings highlight the significance of mesenchymal SMN in neuromusculoskeletal pathogenesis of SMA and provide insights into potential therapeutic strategies targeting mesenchymal cells for the treatment of SMA.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>spinal muscular atrophy</kwd><kwd>fibro-adipogenic progenitor</kwd><kwd>neuromuscular junction</kwd><kwd>growth plate</kwd><kwd>chondrocyte</kwd><kwd>IGF signaling</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>NRF-2022R1A2C3007621</award-id><principal-award-recipient><name><surname>Kong</surname><given-names>Young-Yun</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>NRF-2020R1A5A1018081</award-id><principal-award-recipient><name><surname>Kong</surname><given-names>Young-Yun</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>NRF-2020R1A2C3011464</award-id><principal-award-recipient><name><surname>Choi</surname><given-names>Se-Young</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Fibro-adipogenic progenitors in skeletal muscle contribute to the neuromuscular pathogenesis of spinal muscular atrophy, and depletion of SMN in chondrocytes reduces local IGF sigaling in growth plate.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The survival motor neuron (SMN) protein is a crucial component of the spliceosome complex and is essential for the proper function of all cell types (<xref ref-type="bibr" rid="bib43">Mercuri et al., 2022</xref>). Deficiency in SMN protein disrupts the formation of spliceosome complexes, ultimately causing splicing defects in multiple genes. Mutations in the <italic>SMN1</italic> gene, which encodes the SMN protein, give rise to the neuromuscular disorder spinal muscular atrophy (SMA). SMA is characterized by neuromuscular junctions (NMJs) disruption, muscular atrophy, and alpha motor neuron loss (<xref ref-type="bibr" rid="bib43">Mercuri et al., 2022</xref>; <xref ref-type="bibr" rid="bib6">Burghes and Beattie, 2009</xref>). The severity of the disease in humans correlates with the copy number of <italic>SMN2</italic>, which is a paralog of <italic>SMN1</italic> in humans. <italic>SMN2</italic> primarily produces less functional exon 7-deleted SMN protein and rarely generates a limited quantity of functional full-length SMN protein via alternative splicing. SMA patients are classified into types 0 through 4 based on the severity and timing of disease onset, predominantly determined by the number of copies of the <italic>SMN2</italic> gene they possess. More than 50% of SMA patients are categorized as type 1, characterized by muscle defects with proximal muscle atrophy during infancy, eventually resulting in death within a few years (<xref ref-type="bibr" rid="bib43">Mercuri et al., 2022</xref>).</p><p>Previous studies suggest that the onset of SMA is mainly attributed to SMN loss in motor neurons (<xref ref-type="bibr" rid="bib45">Monani et al., 2000</xref>; <xref ref-type="bibr" rid="bib6">Burghes and Beattie, 2009</xref>). Nevertheless, motor neuron-specific SMN deficiency in the SMA mouse model exhibits relatively mild phenotypes compared to whole-body SMA mouse models (<xref ref-type="bibr" rid="bib51">Park et al., 2010</xref>; <xref ref-type="bibr" rid="bib41">McGovern et al., 2015</xref>). Furthermore, restoring SMN to motor neurons in SMA mouse models result in only partial rescue in lifespan and neuromuscular defects (<xref ref-type="bibr" rid="bib52">Passini et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Martinez et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">McGovern et al., 2015</xref>; <xref ref-type="bibr" rid="bib4">Besse et al., 2020</xref>). Systemic administration of antisense oligonucleotide (ASO), which corrects <italic>SMN2</italic> splicing to restore SMN expression, significantly prolongs survival compared to central nervous system (CNS) administration (<xref ref-type="bibr" rid="bib23">Hua et al., 2011</xref>). In the mouse treated with a systemically delivered ASO, blocking the effect of ASO in the CNS by a complementary decoy did not have any detrimental effect on survival, motor function, or NMJ integrity (<xref ref-type="bibr" rid="bib24">Hua et al., 2015</xref>). These studies suggest that peripheral SMN plays a crucial part in SMA pathology. Overall, investigating the impacts of SMN depletion in peripheral tissues is critical for alleviating neuromuscular impairments and increasing life expectancy in SMA.</p><p>In SMA patients, bone growth retardation has been observed (<xref ref-type="bibr" rid="bib13">De Amicis et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Kipoğlu et al., 2019</xref>; <xref ref-type="bibr" rid="bib21">Hensel et al., 2020</xref>). Studies using whole-body SMA mouse models have revealed that this is caused by diminished growth plate chondrocyte density and endochondral ossification defects, independent of muscle atrophy (<xref ref-type="bibr" rid="bib21">Hensel et al., 2020</xref>). However, it is still unclear whether these defects result from the SMN ablation in bone-forming cells, or from a decline in liver-derived insulin-like growth factor (IGF) in SMA patients and mice (<xref ref-type="bibr" rid="bib23">Hua et al., 2011</xref>; <xref ref-type="bibr" rid="bib77">Yesbek Kaymaz et al., 2016</xref>). In severe SMA mice, the serum levels of IGF decreased by approximately 60% or became undetected (<xref ref-type="bibr" rid="bib23">Hua et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Murdocca et al., 2012</xref>). The decreased serum IGF levels were attributed to decreased expression of liver genes, including <italic>Igf1</italic>, IGF binding, and ternary complex protein gene <italic>Igfals</italic> and <italic>Igfbp3</italic>. The previous studies suggest that the liver is the primary origin of systemic IGF, as demonstrated by the liver-specific deletion of <italic>Igf1</italic> and the knockout of <italic>Igfals</italic>, which is mostly expressed in the liver (<xref ref-type="bibr" rid="bib74">Yakar et al., 1999</xref>; <xref ref-type="bibr" rid="bib75">Yakar et al., 2002</xref>). The double KO mice exhibited a 90% decrease in serum IGF levels and displayed a phenotype of shortened femur length and growth plates. It is thus possible that the decrease in serum IGF levels, resulting from reduced liver IGF pathway genes in SMA mice, has also played a role in the observed bone growth defect.</p><p>Mesenchymal progenitor cells (MPCs) derived from the lateral plate mesoderm (LPM) differentiate into various types of limb mesenchymal cells, including bone, cartilage, and intramuscular mesenchymal cells like fibro-adipogenic progenitors (FAPs) (<xref ref-type="bibr" rid="bib48">Nassari et al., 2017</xref>). Recent studies have revealed the role of FAPs in skeletal muscle homeostasis, as reducing the number of FAPs resulted in diminished muscle regeneration capacity, long-term muscle atrophy, and NMJ denervation (<xref ref-type="bibr" rid="bib73">Wosczyna et al., 2019</xref>; <xref ref-type="bibr" rid="bib65">Uezumi et al., 2021</xref>). Our latest research demonstrated that FAP-specific deficiency of <italic>Bap1</italic>, one of the deubiquitinases, leads to NMJ defects (<xref ref-type="bibr" rid="bib32">Kim et al., 2022</xref>). These recent findings raise the possibility that FAPs may have a specific role in the pathogenesis of neuromuscular diseases such as SMA. However, it has not been studied if depletion of SMN in FAPs can lead to SMA-like neuromuscular pathology.</p><p>In this study, we crossed a limb MPC-specific Cre mouse with a floxed <italic>Smn1</italic> exon 7 mouse carrying multiple copies of the human <italic>SMN2</italic> gene, allowing us to examine the impact of mesenchymal SMN reduction on SMA pathogenesis. As a result, the mutant mice showed skeletal growth abnormalities and local IGF signaling defects in the growth plate. In addition, our findings indicate that the SMN reduction in FAPs, similar to the extent of severe SMA, causes altered NMJ development.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Bone growth restriction and growth plate defects caused by MPC-specific SMN depletion</title><p>To investigate the effects of SMN reduction within MPCs in SMA pathogenesis, we crossed <italic>Smn1<sup>f7/f7</sup></italic> mice, which possess loxP sites flanking exon 7 of the <italic>Smn1</italic> gene (<xref ref-type="bibr" rid="bib17">Frugier et al., 2000</xref>), with <italic>Prrx1<sup>Cre</sup></italic> mice. This produced <italic>Smn1<sup>ΔMPC</sup></italic> mice (<italic>Prrx1<sup>Cre</sup>; Smn1<sup>f7/f7</sup></italic>) that lacked the <italic>Smn1</italic> gene specifically in <italic>Prrx1<sup>Cre</sup></italic>-expressed limb MPCs that give rise to bone, cartilage, and FAPs (<xref ref-type="bibr" rid="bib37">Logan et al., 2002</xref>; <xref ref-type="bibr" rid="bib35">Leinroth et al., 2022</xref>). To ascertain whether mutant mice carrying the <italic>SMN2</italic> gene, like SMA patients, present pathological phenotypes, we additionally generated <italic>SMN2</italic> 2-copy <italic>Smn1<sup>ΔMPC</sup></italic> (<italic>Prrx1<sup>Cre</sup>; Smn1<sup>f7/f7</sup>; SMN2<sup>+/+</sup></italic>) and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> (<italic>Prrx1<sup>Cre</sup>; Smn1<sup>f7/f7</sup>; SMN2<sup>+/0</sup></italic>) mice. Control littermates that lacked <italic>Prrx1<sup>Cre</sup></italic> were used as controls for comparison.</p><p><italic>SMN2</italic> 0-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice died within 24 hr after birth. Regions where limbs should have formed at E18.5 only had rudimentary limb structures (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Furthermore, since the upper head bone did not cover the brain, it was directly attached to the skin and protruded. These observations can be attributed to <italic>Prrx1<sup>Cre</sup></italic>-mediated SMN deletion in the LPM-derived limb MPCs and the craniofacial mesenchyme, which is accountable for the formation of calvarial bone (<xref ref-type="bibr" rid="bib72">Wilk et al., 2017</xref>). To investigate whether the lack of SMN proteins in MPCs is responsible for bone development abnormalities, we performed alcian blue and alizarin red staining on E18.5 <italic>SMN2</italic> 0-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants to analyze the structure of bones and cartilage. The appendages displayed restricted bone and cartilage formations, with scarcely discernible femur and tibia (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B, C</xref>). In the cranial region, there was an absence of both cartilage and bone at the location of the calvarial bone, with the parietal bone entirely missing and partially absent frontal bone (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Additionally, the sternum, which is one of the bones originating from the LPM (<xref ref-type="bibr" rid="bib61">Sheng, 2015</xref>), was shorter than the control (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>).</p><p>The <italic>SMN2</italic> 2-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice, carrying two homologous <italic>SMN2</italic> genes, did not show any discernible differences from the <italic>Prrx1<sup>Cre</sup></italic>-negative control littermates into adulthood. However, the <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice exhibited reduced body size and shorter limb length compared to the <italic>SMN2</italic> 1-copy control (<italic>Smn1<sup>f7/f7</sup>; SMN2<sup>+/0</sup></italic>). To assess postnatal bone growth defects observed in SMA patients and mouse models, we conducted micro-computed tomography (micro-CT) analysis on femurs obtained from postnatal day 14 (P14) <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> and <italic>SMN2</italic> 2-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The 3D reconstruction image showed that the <italic>SMN2</italic> 1-copy mutant femur was smaller than the WT control and <italic>SMN2</italic> 2-copy mutant, and secondary ossification center is denied. The longitudinal virtual section view displayed reduced trabecular bone in the <italic>SMN2</italic> 1-copy mutant femur. CT analysis data showed that <italic>SMN2</italic> 1-copy mutants exhibited reduced femur diaphysis length, diameter, and trabecular bone volume compared to the control group, indicating growth plate-dependent endochondral ossification defects (<xref ref-type="fig" rid="fig1">Figure 1B–D</xref>). We then examined femoral bone thickness and diaphyseal bone mineral density (BMD) to determine whether mineralization was normal after bone formation. The thickness of the bone in the mutants did not differ significantly from the control, suggesting that bone mineralization was intact (<xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). Unexpectedly, BMD slightly increased in <italic>SMN2</italic> 1-copy mutants compared to the control group (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). To assess the impact of osteoclasts and osteoblasts on diaphysis cortical bone mineralization, we utilized <italic>Itgb3</italic> immunofluorescence as the osteoclast marker and toluidine blue staining for imaging bone-attached osteoblasts (<xref ref-type="bibr" rid="bib57">Romeo et al., 2019</xref>; <xref ref-type="bibr" rid="bib9">Colaianni et al., 2015</xref>). Osteoclast and osteoblast density did not significantly differ between the <italic>SMN2</italic> 1-copy mutant and the control (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C–E</xref>). The higher BMD may be attributed to greater mechanical stress caused by the shorter femur supporting the weight of the body, consistent with prior research indicating that elevated mechanical force leads to higher BMD in the femur (<xref ref-type="bibr" rid="bib22">Hoxha et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Ike et al., 2015</xref>). Nevertheless, the decrease in bone growth without apparent deterioration in bone mineralization of the femur of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants is consistent with findings from the whole-body SMA mouse model (<xref ref-type="bibr" rid="bib21">Hensel et al., 2020</xref>). Collectively, these results suggest that mice carrying low copies of <italic>SMN2</italic>, with the <italic>Smn1</italic> gene specifically deleted in MPCs, exhibit bone growth abnormalities, while osteoblast and osteoclast populations show no obvious defects based on our preliminary analyses.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Skeletal growth abnormalities and altered growth plate homeostasis in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice.</title><p>(<bold>A</bold>) Representative 3D images and longitudinal section view of the ossified femur bone. Scale bars, 1 mm. (<bold>B, C</bold>) <italic>SMN2</italic> 1-copy mutant’s femurs showed reduced growth in diaphysis length and diameter, and (<bold>D</bold>) decreased trabecular bone volume. (<bold>E</bold>) Trabecular bone thicknesses were not significantly different between the control and mutant groups. The micro-computed tomography (micro-CT) analysis was performed in femur diaphysis and metaphysis from <italic>SMN2</italic> 1-copy <italic>Smn1</italic><sup>ΔWT</sup>, <italic>SMN2</italic> 2-copy, and 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at P14. One-way analysis of variance (ANOVA) with Tukey’s post hoc test, <italic>n</italic> = 3–5 mice in each genotype (<bold>B–E</bold>). (<bold>F</bold>) Representative images of hematoxylin and eosin (H&amp;E) staining in the distal femur growth plate of control and mutant mice with 1 copy of <italic>SMN2</italic> at P14. Scale bars, 100 μm. Resting zone (RZ), hypertrophic zone (HZ), and proliferative zone (PZ). (<bold>G–I</bold>) Indicated by black arrows, the HZ and PZ lengths were reduced in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice, and the hypertrophic cell number in a section of the 1-copy mutant was decreased (<italic>n</italic> = 4 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction). (<bold>J</bold>) Representative images of Ki67 immunostaining in the distal femur growth plate of control and mutant mice with 1 copy of <italic>SMN2</italic> at P14. Scale bars, 100 μm, and (<bold>K</bold>) decreased Ki67+ percentage in resting zone chondrocytes. (<bold>L</bold>) Ki67+ percentage in the proliferative zone was not significantly different between the control and mutant groups. <italic>n</italic> = 3 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction (<bold>K–L</bold>). ns: not significantly different. *p &lt; 0.05; **p &lt; 0.01. Error bars show standard error of the mean (SEM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92731-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Growth defects in the <italic>Prrx1</italic>-lineage bone of <italic>SMN2</italic> 0-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice.</title><p>(<bold>A</bold>) Representative control and mutant mice with 0 copies of <italic>SMN2</italic> were photographed at E18.5. (<bold>B, C</bold>) Alcian blue and alizarine red staining in the <italic>SMN2</italic> 0-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant showed abnormal skeletal development of the limbs, (<bold>D</bold>) calvaria (shown by the dashed line), and (<bold>E</bold>) sternum (indicated by a white arrow). Scale bars, 5 mm (<bold>B, C</bold>) and 2 mm (<bold>D, E</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92731-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Osteoclasts and osteoblasts were undisturbed in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice.</title><p>(<bold>A</bold>) Cortical bone thicknesses were not significantly different between the control and mutant groups. (<bold>B</bold>) Bone mineral density was slightly increased in the diaphysis of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice. The micro-computed tomography (micro-CT) analysis was performed in femur diaphysis and metaphysis from <italic>SMN2</italic> 1-copy <italic>Smn1<sup>WT</sup></italic>, <italic>SMN2</italic> 2-copy, and 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at P14. One-way analysis of variance (ANOVA) with Tukey’s post hoc test, <italic>n</italic> = 3–5 mice in each genotype (<bold>A, B</bold>). (<bold>C</bold>) Representative images of osteoclast marker Itgb3 immunostaining in femur diaphysis cortical bone from mice at P14. Scale bars, 100 μm. Itgb3+ hematopoietic cell (indicated by arrow) and osteoclast (indicated by arrowhead) were imaged. (<bold>D</bold>) It showed similar osteoclast density. <italic>n</italic> = 3 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction. (<bold>E</bold>) Representative images of toluidine blue staining in femur diaphysis cortical bone for osteoblast evaluation. Scale bars, 100 μm. ns: not significantly different. *p &lt; 0.05. Error bars show standard error of the mean (SEM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92731-fig1-figsupp2-v1.tif"/></fig></fig-group><p>Various bone-forming cells originating from the LPM were known to contribute to bone formation, such as growth plate chondrocytes and osteoblasts. In <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants, SMN may be deleted in these cells, suggesting that they play a role in the bone growth abnormalities observed in 2-week-old mice. Previous researchers revealed that primary osteoblasts from a severe SMA mouse model did not display notable differences from controls in an in vitro ossification test. And they did not observe any differences in bone voxel density and bone thickness in femurs at P3 severe SMA mice. This is supported by the absence of any bone thickness or BMD defects in the <italic>SMN2</italic> 1-copy mutant (<xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B</xref>), and the unimpaired osteoblast population (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>). Thus, we conclude that the bone growth abnormalities observed in the 2-week-old <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant are due to impaired endochondral ossification.</p><p>To determine whether bone growth defects in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants arise from disrupted chondrocyte homeostasis at growth plates, we stained the femur distal growth plate of P14 mice with hematoxylin and eosin (H&amp;E; <xref ref-type="fig" rid="fig1">Figure 1F</xref>). In line with earlier findings in whole-body SMA mice (<xref ref-type="bibr" rid="bib21">Hensel et al., 2020</xref>), <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice exhibited shorter proliferative and hypertrophic zones compared to control mice (<xref ref-type="fig" rid="fig1">Figure 1G, H</xref>). Additionally, there was a significant reduction in the number of chondrocytes in the hypertrophic zone (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). To investigate the decrease in chondrocyte proliferation and subsequent reduction in the proliferative and hypertrophic zone, we stained the proliferation marker Ki67 in the growth plate of both <italic>SMN2</italic> 1-copy control and mutant samples (<xref ref-type="fig" rid="fig1">Figure 1J</xref>). We then quantified the percentage of Ki67+ nuclei in the resting and proliferative zones (<xref ref-type="fig" rid="fig1">Figure 1K, L</xref>). Although there was no significant difference observed in the Ki67+ percentage of proliferative zone chondrocytes in the proceeding proliferation state, there was an absolute reduction in resting zone chondrocyte proliferation. The decreased proliferation rate in the resting zone could have impeded the transition to the proliferative zone. Our data indicate that adequate expression of SMN is essential for the homeostasis of chondrocytes at growth plates.</p></sec><sec id="s2-2"><title>Disruption of chondrocyte-derived IGF signaling in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants</title><p>The proliferation and differentiation of growth plate chondrocytes are regulated by systemic IGF (<xref ref-type="bibr" rid="bib62">Shim, 2015</xref>; <xref ref-type="bibr" rid="bib27">Karimian et al., 2011</xref>; <xref ref-type="bibr" rid="bib56">Racine and Serrat, 2020</xref>). Previous research suggested that a key factor contributing to the pathological phenotype in SMA is the lowered expression of the <italic>Igf1/Igfbp3/Igfals</italic> genes, which produce IGF and IGF-carrying proteins, in the liver (<xref ref-type="bibr" rid="bib23">Hua et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Murdocca et al., 2012</xref>). As the IGF pathway proteins are downregulated in whole-body SMA mice, the bone growth defects observed in the mice have sparked debate as it remains unclear whether they are due to cell-autonomous defects by bone-forming cells’ SMN reduction, or the low liver-derived IGF level (<xref ref-type="bibr" rid="bib23">Hua et al., 2011</xref>; <xref ref-type="bibr" rid="bib64">Tsai et al., 2014</xref>; <xref ref-type="bibr" rid="bib14">Deguise et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Hensel et al., 2020</xref>).</p><p>To clarify this issue, we used <italic>Smn1<sup>ΔMPC</sup></italic> mutant mice, which enabled us to investigate the effect of SMN depletion in bone-forming cells such as chondrocytes on bone growth, while circumventing the impact of the endocrine signal by <italic>Prrx1</italic>-negative organ. To investigate the impact of IGF signaling on growth plate chondrocytes, we employed immunofluorescence to evaluate the percentage of p-AKT-positive cells activated by the IGF–PI3K–AKT pathway in both <italic>SMN2</italic> 1-copy control and mutant femur distal growth plate (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Intriguingly, the percentage of p-AKT+ cells was significantly decreased in resting zone chondrocytes, but not in the proliferative zone, which aligns with the Ki67+ percentage (<xref ref-type="fig" rid="fig2">Figure 2B, C</xref>). Expectedly, the liver’s mRNA expression of IGF pathway genes, reported to be decreased in SMA mouse models and patients (<xref ref-type="bibr" rid="bib23">Hua et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Murdocca et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Deguise et al., 2021</xref>; <xref ref-type="bibr" rid="bib59">Sahashi et al., 2013</xref>), showed no difference when comparing controls to <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). These findings indicate that the growth plate’s proliferation and hypertrophy in <italic>SMN2</italic> 1-copy mutants are affected by impairments in another AKT upstream signal rather than by liver-secreted systemic IGF.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Decreased chondrocyte-derived IGF–AKT axis by limb mesenchymal cell-specific survival motor neuron (SMN) depletion in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice.</title><p>(<bold>A</bold>) Representative images of p-AKT immunostaining in distal femur growth plate from mice at P14. Scale bars, 100 μm. (<bold>B, C</bold>) The p-AKT-positive percentage was decreased in the resting zone chondrocytes, not in the proliferative zone (<italic>n</italic> = 3–4 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction). (<bold>D</bold>) Relative IGF axis mRNA expression in the livers of <italic>SMN2</italic> 1-copy control and mutant mice. The IGF pathway genes showed no difference when comparing controls to <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants. (<bold>E, F</bold>) Relative IGF axis and chondrocyte differentiation marker mRNA expression in the chondrocytes of <italic>SMN2</italic> 1-copy control and mutant mice. The <italic>Igf1</italic>, <italic>Igfbp3</italic>, and hypertrophic marker <italic>Col10a1</italic> expression were decreased in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants. <italic>n</italic> = 3 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction (<bold>D–F</bold>). (<bold>G</bold>) Representative images of genomic PCR analysis from <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice tissues at P21. (<bold>H</bold>) Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis from tissues of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>WT</sup></italic> and <italic>Smn1<sup>ΔMPC</sup></italic> mice at P21 (<italic>n</italic> = 3 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction). Deletion of <italic>Smn1</italic> exon 7 was detected only in limb mesenchymal cells using genomic PCR (<bold>G</bold>) and full-length <italic>Smn1</italic> mRNA expression (<bold>H</bold>). (<bold>I</bold>) Representative images of western blot analysis in cultured fibro-adipogenic progenitors (FAPs). SMN protein in FAPs of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice exhibited a decrease comparable to that observed in the SMAΔ7 mice. (<bold>J</bold>) Relative SMN levels in cultured FAPs of the controls and mutants (<italic>n</italic> = 3 mice in each genotype; one-way analysis of variance (ANOVA) with Tukey’s post hoc test). ns: not significantly different. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001; ****p &lt; 0.001. Error bars show standard error of the mean (SEM).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original file for the gel electrophoresis of genomic PCR in <xref ref-type="fig" rid="fig2">Figure 2G</xref> (<italic>Cre</italic>, <italic>Smn1<sup>F7</sup></italic>, <italic>Smn1<sup>Δ7</sup></italic>) and western blot analysis in <xref ref-type="fig" rid="fig2">Figure 2I</xref> (anti-alpha-tubulin, anti-SMN).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92731-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig2">Figure 2G, I</xref> and original scans of the PCR and western blot with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92731-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92731-fig2-v1.tif"/></fig><p>There are reports indicating that local IGF expression plays a crucial role in bone development through the growth plate, in addition to circulating IGF (<xref ref-type="bibr" rid="bib19">Hallett et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Racine and Serrat, 2020</xref>). While most <italic>Igf1</italic>-null mice died before birth and had smaller tibial lengths than normal, liver-specific <italic>Igf1</italic>-deleted mice did not experience significant changes in body length or tibial length during postnatal growth, despite a 75% reduction in serum IGF-1 levels (<xref ref-type="bibr" rid="bib2">Baker et al., 1993</xref>; <xref ref-type="bibr" rid="bib74">Yakar et al., 1999</xref>). This indicates that local IGF in the growth plate is crucial for endochondral ossification, in addition to serum IGF. The chondrocyte-specific Igf1 knockout mouse demonstrated a reduction in postnatal body and femur length, and the chondrocyte-specific <italic>Igf1r</italic> knockout mouse demonstrated a significant reduction in bone growth, as well as a decrease in both growth plate proliferative and hypertrophic zone (<xref ref-type="bibr" rid="bib18">Govoni et al., 2007</xref>; <xref ref-type="bibr" rid="bib70">Wang et al., 2011</xref>). A recent study revealed that resting zone chondrocytes in the growth plate serve as a major source of local IGF and activate the p-AKT pathway via autocrine and paracrine IGF signaling (<xref ref-type="bibr" rid="bib49">Oichi et al., 2023</xref>). The study further revealed that cells that constitute bone and bone marrow, apart from chondrocytes, do not express <italic>Igf1</italic>, making chondrocytes the solitary source of local IGF. These suggest that the growth plate defects and the reduction of resting zone AKT phosphorylation in <italic>SMN2</italic> 1-copy mutants may be due to chondrocyte-secreted IGF deficiency. To confirm this hypothesis, we evaluated the expression of IGF-related genes in chondrocytes from both <italic>SMN2</italic> 1-copy control and mutant femur (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Indeed, <italic>Igf1</italic> and <italic>Igfbp3</italic> were greatly depleted in <italic>SMN2</italic> 1-copy mutant chondrocytes. It is hypothesized that the increased presence of <italic>Ghr</italic> may be in response to the reduction of <italic>Igf1</italic>. As IGF directly causes chondrocyte hypertrophy (<xref ref-type="bibr" rid="bib69">Wang et al., 1999</xref>), we assess the mRNA expression of chondrocyte hypertrophic marker <italic>Col10a1</italic> and undifferentiated chondrocyte marker <italic>Col2a1</italic> (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). The results show that <italic>Col10a1</italic> is decreased, while <italic>Col2a1</italic> is increased in the mutant. In <xref ref-type="fig" rid="fig1">Figure 1H, I</xref>, the hypertrophic cell reduction may be caused by a low local IGF level. Therefore, depletion of local IGF in the growth plate of <italic>SMN2</italic> 1-copy mutants may hinder chondrocyte progression to proliferation and hypertrophy, leading to aberrations in endochondral ossification. In <xref ref-type="fig" rid="fig1">Figures 1L</xref> and <xref ref-type="fig" rid="fig2">2C</xref>, it is possible that the serum IGF could affect the remnant proliferative and p-AKT-positive cells in the growth plate via the vascularization of bone marrow. Based on these findings, it was concluded that deprivation of SMN in chondrocytes leads to a decrease in local IGF signaling, which affects growth plate homeostasis.</p></sec><sec id="s2-3"><title>Mesenchymal cell-specific SMN reduction similar to severe SMA mouse model in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants</title><p>To confirm the specific deletion of <italic>Smn1</italic> in limb mesenchymal cells, including chondrocytes and FAPs, we performed quantitative reverse transcription polymerase chain reaction (qRT-PCR) for full-length <italic>Smn1</italic> mRNA expressed by undeleted <italic>Smn1</italic> allele. Our findings indicate that full-length <italic>Smn1</italic> mRNA expression in the brain, liver, skeletal muscle, and spinal cord of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at postnatal day 21 (P21) was similar to that of control mice, while it was significantly reduced in isolated FAPs and chondrocytes (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). Additionally, we confirmed the presence of the <italic>Smn1</italic><sup>Δ7</sup> variant, which is the exon 7-deleted form of <italic>Smn1</italic> created by cre-lox-mediated recombination, in both FAPs and chondrocytes by conducting genomic PCR on the <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Since SMN was not downregulated in the tissues other than limb mesenchymal cells, non-mesenchymal cells were ruled out from being responsible for the phenotype observed in <italic>Smn1<sup>ΔMPC</sup></italic> mutants.</p><p>Among our <italic>Smn1<sup>ΔMPC</sup></italic> models, mice with two copies of <italic>SMN2</italic> exhibit similar bone development parameters as control mice without SMN deletion. However, mice with one copy of <italic>SMN2</italic> display bone pathological defects akin to SMA mouse models. This may be because the quantity of human full-length SMN protein produced by <italic>SMN2</italic> 2-copy, was sufficient to sustain SMN complex function in the <italic>SMN2</italic> 2-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants, despite the absence of functional mouse SMN protein in limb mesenchymal cells. On the contrary, due to the lower expression of full-length SMN compared to <italic>SMN2</italic> 2-copy mutants, the SMN complex may not function properly in <italic>SMN2</italic> 1-copy mutant cells. We confirmed this by comparing the amount of full-length SMN protein in isolated FAPs from the hindlimbs of control, <italic>Smn1<sup>ΔMPC</sup></italic> mutants, and a severe SMA mouse model (<italic>Smn1<sup>−/−</sup>; SMN2<sup>+/+</sup>; SMNΔ7<sup>+/+</sup></italic>; SMAΔ7 mutants) (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). The data show that <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants exhibited ~80% reduction in SMN levels compared to the control group. The level of SMN protein in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants was similar to that in SMAΔ7 mutants. Conversely, <italic>SMN2</italic> 2-copy mutants display a decrease of approximately 40% in SMN protein levels compared to the control (<xref ref-type="fig" rid="fig2">Figure 2J</xref>). The moderately reduced expression of SMN is adequate to support regular bone development in <italic>SMN2</italic> 2-copy mutants. Taken together, our findings indicate that the reduction of mesenchymal SMN to levels comparable to that of the severe SMA mouse model causes SMA-like bone pathology in the <italic>SMN2</italic> 1-copy mutant.</p></sec><sec id="s2-4"><title>Abnormal NMJ maturation in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants</title><p>To investigate whether disabling SMN in FAPs results in SMA-like neuromuscular impairments, we assessed if NMJ phenotypes observed in SMA mouse models also occur in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants. Both severe and mild SMA mouse models exhibit impaired NMJ maturation markers, including plaque-like morphology of acetylcholine receptor (AChR) clusters, neurofilament (NF) varicosities, and poor terminal arborization (<xref ref-type="bibr" rid="bib34">Kong et al., 2009</xref>; <xref ref-type="bibr" rid="bib39">Martinez et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Monani et al., 2003</xref>; <xref ref-type="bibr" rid="bib28">Kariya et al., 2008</xref>). To evaluate the impact of SMN deficiency in FAPs on NMJ maturation, we evaluated the NMJ maturation markers in the tibialis anterior (TA) muscles of control and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant mice at P21, a time when NMJ maturation is in progress (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Our examination revealed the presence of NF varicosities in <italic>SMN2</italic> 1-copy mutants as compared with control mice (<xref ref-type="fig" rid="fig3">Figure 3A, D</xref>). Additionally, the number of nerve branches was decreased and half of the total NMJs were poorly arborized in <italic>SMN2</italic> 1-copy mutants (<xref ref-type="fig" rid="fig3">Figure 3B, C</xref>). These presynaptic alterations are specific phenotypes in neurogenic atrophy-like SMA. Unlike neurogenic atrophy, physiologic atrophy shows no differences in presynaptic morphology, such as nerve branching (<xref ref-type="bibr" rid="bib15">Deschenes et al., 2006</xref>). This suggests that the NMJ phenotypes observed in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant mice are not caused by decreased muscle size and activity resulting from bone growth abnormalities. The morphology of AChR clusters shows that the mutants have more immature plaque-like NMJs than the controls’ pretzel-like structure (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Therefore, these findings indicate that <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants exhibit NMJ maturation abnormalities common in SMA mouse models.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Aberrant postnatal neuromuscular junction (NMJ) maturation in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice.</title><p>(<bold>A</bold>) Immunostaining of NMJs in TA muscle of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>WT</sup></italic> and <italic>Smn1<sup>ΔMPC</sup></italic> mice at P21 with anti-NF (green), anti-synaptophysin (blue), and α-Btx staining acetylcholine receptor (AChR; red). Scale bars, 20 μm. The confocal images of NMJs showed decreased presynaptic terminal branching and the existence of nerve terminal varicosities that were enlarged with neurofilament (NF; indicated by arrowheads) in the mutant. (<bold>B</bold>) The NMJs of the <italic>SMN2</italic> 1-copy mutant exhibited a significant decrease in presynaptic terminal arborization and (<bold>C</bold>) an increased percentage of poorly arborized NMJs (<italic>n</italic> = 3 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction). (<bold>D</bold>) The percentage of NMJs exhibiting NF varicosities was higher in the <italic>SMN2</italic> 1-copy mutant group than in the control group (<italic>n</italic> = 3–4 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction). (<bold>E</bold>) For quantification of the NMJ maturation stage, we classified NMJs into five distinct developmental stages (Plaque: plaque-shaped endplate without any perforation; Small perforated: plaque-shaped endplate with small perforations; Large perforated: plaque-shaped endplate with large perforations; Open: C-shaped endplate; Pretzel: pretzel-like shaped endplate) and then compared the frequency patterns of <italic>SMN2</italic> 1-copy control and mutant mice (<italic>n</italic> = 3 mice in each genotype; two-way analysis of variance (ANOVA) with Tukey’s post hoc test). The NMJs of <italic>SMN2</italic> 1-copy mutants displayed plaque-like shapes, indicating that they were in the immature stage. (<bold>F</bold>) Immunostaining of NMJs in TA muscle of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>WT</sup></italic> and <italic>Smn1<sup>ΔMPC</sup></italic> mice at P3 with anti-NF (green), anti-synaptophysin (blue), and α-Btx staining AChR (red). Scale bars, 10 μm. (<bold>G</bold>) There were no significant differences in AChR cluster size between the <italic>SMN2</italic> 1-copy control and mutant at P3 (<italic>n</italic> = 3–4 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction). (<bold>H</bold>) The ratio of the Synaptophysin area to the AChR area in NMJ was slightly higher in the <italic>SMN2</italic> 1-copy mutant at P3 (<italic>n</italic> = 3–4 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction). ns: not significantly different. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001; ****p &lt; 0.0001. All box-and-whisker plots show the median, interquartile range, minimum, and maximum. For the box-and-whisker plots, range bars show minimum and maximum (<bold>B, G, H</bold>). For the bar and line graph, error bars show standard error of the mean (SEM) (<bold>C–E</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92731-fig3-v1.tif"/></fig></sec><sec id="s2-5"><title>Undisturbed NMJ formation in neonatal <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants</title><p>To determine whether any NMJ defects were present prior to juvenile NMJ maturation in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic>, we examined NMJ formation in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at the neonatal stage on postnatal day 3. We evaluated the AChR and nerve terminal areas to assess post- and presynaptic development, respectively (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Measurements of AChR cluster size indicated no differences between control and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). However, the area of AChR covered by nerve terminals was slightly larger in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). We have no reasonable explanation for why the coverage is higher in the mutant. However, there does not appear to be abnormal development of the NMJ in the mutant, at least until the neonatal period. Therefore, we reasoned that <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants began to exhibit deterioration in the NMJ maturation during the juvenile stage, following the intact neonatal development of NMJ.</p></sec><sec id="s2-6"><title>Aberrant NMJ morphology in the adult <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice</title><p>To evaluate the organization of NMJ after the conclusion of postnatal NMJ development, considering mesenchymal SMN expression, we examined NMJ morphology in the TA muscle of control, <italic>SMN2</italic> 1-copy, and 2-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at postnatal day 56 (P56). Our analysis revealed that presynapses were fragmented in <italic>SMN2</italic> 1-copy mutants, resulting in a bouton-like morphology, in contrast to the control and <italic>SMN2</italic> 2-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice, a twofold presynaptic fragmentation compared to the control was quantified, demonstrating nerve terminal shrinkage (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Additionally, NF ends displayed more severe varicosities than at P21 and were only connected to the proximal nerve by very thin NF, unlike control and <italic>SMN2</italic> 2-copy mice (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Remarkably, numerous presynaptic islands formed in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice through the merging of fragmented presynapses and NF varicosity. In <italic>SMN2</italic> 1-copy mutants, AChR clusters displayed fragmented grape-shaped morphology that overlapped with nerve terminals, whereas control and <italic>SMN2</italic> 2-copy mice displayed pretzel-like structures (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). These results suggest that defects in adult NMJ morphology occur when mesenchymal SMN protein is reduced to the extent of the <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Morphological deterioration in neuromuscular junctions (NMJs) of adult <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice.</title><p>(<bold>A</bold>) Immunostaining of NMJs in TA muscle of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>WT</sup></italic>, <italic>SMN2</italic> 2-copy, and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at P56 with anti-NF (green), anti-synaptophysin (blue), and α-Btx staining acetylcholine receptor (AChR; red). Scale bars, 20 μm. The confocal images of NMJs showed fragmentation and bouton-like neurofilament (NF) varicosities (indicated by arrowheads) in the <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice. The NMJs of the <italic>SMN2</italic> 1-copy mutant displayed fragmented presynapse (<bold>B</bold>), endplate (<bold>D</bold>), and NF varicosities (<bold>C</bold>) compared to <italic>SMN2</italic> 1-copy <italic>Smn1<sup>WT</sup></italic> and <italic>SMN2</italic> 2-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice (<italic>n</italic> = 3–5 mice in each genotype; Presynaptic fragments and AChR fragments: Brown–Forsythe and Welch analysis of variance (ANOVA) with Games–Howell’s test; NF varicosities: one-way ANOVA with Tukey’s post hoc test). ns; not significantly different. ****p &lt; 0.0001. All box-and-whisker plots show the median, interquartile range, minimum, and maximum. For the box-and-whisker plots, range bars show minimum and maximum (<bold>B, D</bold>). For the bar graph, error bars show standard error of the mean (SEM) (<bold>C</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92731-fig4-v1.tif"/></fig></sec><sec id="s2-7"><title>Presynaptic neurotransmission alteration in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants</title><p>To investigate whether the morphologically aberrant NMJs of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice have functional impairments, we isolated hindlimb extensor digitorum longus (EDL) muscles from P56 mice and conducted electrophysiological recording. We incubated the muscles with μ-conotoxin, which selectively inhibits muscle voltage-gated Na<sup>+</sup> channels, prevented the induction of muscle action potential (<xref ref-type="bibr" rid="bib36">Ling et al., 2010</xref>; <xref ref-type="bibr" rid="bib78">Zanetti et al., 2018</xref>), and recorded the Miniature endplate potential (mEPP) and evoked endplate potential (eEPP) (<xref ref-type="bibr" rid="bib36">Ling et al., 2010</xref>; <xref ref-type="bibr" rid="bib78">Zanetti et al., 2018</xref>). mEPP, a response that occurs when spontaneously released acetylcholine binds to nicotinic AChR without nerve stimulation, was measured ex vivo near the NMJs of the EDL muscles in the control and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The mEPP amplitude was increased in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), whereas mEPP frequency was comparable between the controls and mutants (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The results indicate that the NMJ synapses of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice are functional and more sensitive to acetylcholine compared to the controls. Next, we measured the eEPP by stimulating an action potential at the peroneal nerve (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Despite the increased mEPP amplitude, the amplitude of eEPPs was significantly decreased in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). These results suggest that the nerve terminals in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice exhibit decreased quantal content. This could be due to a decrease in vesicle release probability. Notably, there was no difference in the paired-pulse response, indicating normal neurotransmitter release probability (<xref ref-type="fig" rid="fig5">Figure 5F, G</xref>). Taken together, these findings suggest that the presynaptic neurotransmission ability of the NMJ is reduced in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Reduced presynaptic neurotransmission ability in the neuromuscular junctions (NMJs) of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice.</title><p>(<bold>A</bold>) Representative traces of Miniature endplate potential (mEPP) from <italic>SMN2</italic> 1-copy <italic>Smn1</italic><sup>ΔWT</sup> (top) and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> (bottom) mice. (<bold>B, C</bold>) <italic>SMN2</italic> 1-copy mutant’s NMJs showed an increase in mEPP amplitude and no differences in mEPP frequency (1-copy control, <italic>n</italic> = 25, 9 mice; 1-copy mutant, <italic>n</italic> = 21, 8 mice; unpaired <italic>t</italic>-test with Welch’s correction). (<bold>D</bold>) Representative traces of evoked endplate potential (eEPP) from <italic>SMN2</italic> 1-copy <italic>Smn1</italic><sup>ΔWT</sup> (top) and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> (bottom) mice. (<bold>E</bold>) The mutant’s NMJs showed a stronger amplitude of eEPPs (1-copy control, <italic>n</italic> = 12, 4 mice; 1-copy mutant, <italic>n</italic> = 12, 3 mice; unpaired <italic>t</italic>-test with Welch’s correction). (<bold>F</bold>) Representative traces of paired-pulse response from <italic>SMN2</italic> 1-copy <italic>Smn1</italic><sup>ΔWT</sup> (top) and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> (bottom) mice. (<bold>G</bold>) Paired-pulse response was not different between <italic>SMN2</italic> 1-copy control and mutant NMJs, indicating a comparable neurotransmitter release probability (1-copy control, <italic>n</italic> = 8, 3 mice; 1-copy mutant, <italic>n</italic> = 6, 3 mice; unpaired <italic>t</italic>-test with Welch’s correction). The electrophysiological recording was performed in the extensor digitorum longus (EDL) muscle at P56. ns: not significantly different. *p &lt; 0.05. All box-and-whisker plots show the median, interquartile range, minimum, and maximum. For the box-and-whisker plots, range bars show minimum and maximum (<bold>B, C, E, G</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92731-fig5-v1.tif"/></fig></sec><sec id="s2-8"><title>Disturbed nerve terminal structure in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice</title><p>To examine the NMJ ultrastructure of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants, we utilized transmission electron microscopy (TEM) (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The density of junctional folds in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant specimens was comparable to that of the control (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). However, the density of synaptic vesicles was substantially elevated in the <italic>SMN2</italic> 1-copy mutants (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Since previous electrophysiological results suggested a decrease in presynaptic neurotransmission capacity in <italic>SMN2</italic> 1-copy mutants, this could be due to synaptic vesicles failing to fuse with the membrane, leading to the accumulation of vesicles in the terminal and reduced quantal contents in <xref ref-type="fig" rid="fig5">Figure 5</xref>. In <xref ref-type="fig" rid="fig3">Figure 3H</xref>, larger synaptophysin coverage in the mutant may be caused by this synaptic vesicle accumulation. Additionally, the detachment of the nerve terminal is more frequent at the NMJ of mutants (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). The detachment of nerve terminals observed in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants could have also resulted in diminished presynaptic neurotransmission capacity. Collectively, these findings indicate that <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants have nerve terminal-specific pathological defects at the NMJ ultrastructural level.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Abnormal nerve terminal ultrastructure in <italic>SMN2</italic> 1-copy mutant.</title><p>(<bold>A</bold>) Representative transmission electron microscopy (TEM) images from neuromuscular junctions (NMJs) of <italic>SMN2</italic> 1-copy <italic>Smn1</italic><sup>ΔWT</sup> and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at P56. Scale bars, 500 nm. Nerve terminal (NT; indicated by the blue zone). Synaptic vesicles (SVs). Muscle fiber (MS; indicated by the red zone). Endplate junctional folds (JF). Nerve terminal detachment (indicated by arrow) was observed in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice. (<bold>B</bold>) The density of junctional folds in the NMJ of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice no significant change compared to the control, whereas (<bold>C</bold>) the density of synaptic vesicles was increased (<italic>n</italic> = 3–4 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction). (<bold>D</bold>) The detachment of the nerve terminal occurs more frequently at the NMJ of mutants (<italic>n</italic> = 3–4 mice in each genotype; unpaired <italic>t</italic>-test with Welch’s correction). ns: not significantly different. *p &lt; 0.05; ***p &lt; 0.001. All box-and-whisker plots show the median, interquartile range, minimum, and maximum. For the box-and-whisker plots, range bars show minimum and maximum (<bold>B, C</bold>). For the bar graph, error bars show standard error of the mean (SEM) (<bold>D</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92731-fig6-v1.tif"/></fig></sec><sec id="s2-9"><title>FAPs transplantation rescues NMJ morphology in limb mesenchymal SMN mutants</title><p>SMN-deleted limb mesenchymal tissues in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutants comprise not only FAPs, but also bone, cartilage, pericytes, and tendon, among others (<xref ref-type="bibr" rid="bib35">Leinroth et al., 2022</xref>; <xref ref-type="bibr" rid="bib48">Nassari et al., 2017</xref>). To evaluate the critical role of FAPs in the postnatal development of the NMJ, we isolated fluorescent protein-labeled wild-type FAPs from <italic>Prrx1<sup>Cre</sup>; Rosa26<sup>LSL-YFP/+</sup></italic> or <italic>Prrx1<sup>Cre</sup>; Rosa26 <sup>LSL-tdTomato/+</sup></italic> mice and transplanted them into the TA muscles of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at postnatal day 10. The TA muscle on the contralateral side was treated with a vehicle as a control. In <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at P56, the muscle that received FAPs showed decreased presynaptic fragmentation, NF varicosities, and postsynaptic fragmentation compared to the contralateral muscle (<xref ref-type="fig" rid="fig7">Figure 7A–D</xref>). As a result, the transplanted muscle was not significantly different from the control except for NF varicosities. These data demonstrate that the transplantation of wild-type FAPs rescues the abnormal NMJ development in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice. Overall, our findings indicate that SMN depletion in FAPs leads to the neuronal SMN-independent NMJ pathology in severe SMA, which is rescued by the transplantation of healthy FAPs.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Improved postnatal neuromuscular junction (NMJ) development in the TA muscle of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice following healthy fibro-adipogenic progenitors (FAPs) transplantation.</title><p>(<bold>A</bold>) Immunostaining of NMJs in tdTomato<sup>+</sup> FAP-transplanted TA muscle (+FAP) and vehicle-treated contralateral muscle (+Veh) in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at P56 with anti-NF (yellow), anti-synaptophysin (blue), α-Btx staining acetylcholine receptor (AChR; green), and tdTomato fluorescence (red). Scale bars, 40 μm. The images revealed neurofilament (NF) varicosities (indicated by arrowheads) in the +Veh NMJs. The tdTomato<sup>+</sup> FAPs (marked by asterisks) were transplanted into +FAP NMJs, which exhibited (<bold>B</bold>) decreased presynaptic fragmentation, (<bold>C</bold>) NF varicosities, and (<bold>D</bold>) AChR fragmentation compared to +Veh NMJs and similar to wild-type NMJs (<italic>n</italic> = 3–4 mice in each group; unpaired <italic>t</italic>-test with Welch’s correction). ns: not significantly different. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001. All box-and-whisker plots show the median, interquartile range, minimum, and maximum. For the box-and-whisker plots, range bars show minimum and maximum (<bold>B, D</bold>). For the bar graph, error bars show standard error of the mean (SEM) (<bold>C</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92731-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this paper, we elucidate the contribution of SMN depletion in mesenchymal progenitors for the pathogenesis of SMA. To test this hypothesis, we generated conditional knockout mouse strains to delete the <italic>Smn1</italic> allele specifically in limb mesenchymal cells and carry human <italic>SMN2</italic> copies. Our research using these mouse models resulted in three major discoveries. First, SMN deficiency in FAPs contributes to NMJ pathological defects in SMA. We observed delayed NMJ maturation and varicosities in juvenile <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant. The pathogenic NMJ phenotypes were also observed in the SMAΔ7 mutant, which is one of the severe SMA mouse models (<xref ref-type="bibr" rid="bib34">Kong et al., 2009</xref>; <xref ref-type="bibr" rid="bib39">Martinez et al., 2012</xref>; <xref ref-type="bibr" rid="bib28">Kariya et al., 2008</xref>). As the SMAΔ7 mutant typically lives for approximately 12 days, the fragmentation of the NMJ in adult <italic>SMN2</italic> 1-copy mutant was not evaluated in the severe SMA mutant. Nevertheless, models that induce a conditional adult SMN deficiency through either Cre<sup>ER</sup> allele or oligonucleotide administration resulting in SMN reduction, demonstrated the depletion of SMN throughout the body caused fragmentation of NMJ (<xref ref-type="bibr" rid="bib59">Sahashi et al., 2013</xref>; <xref ref-type="bibr" rid="bib29">Kariya et al., 2014</xref>). Thus, we demonstrate that the <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant model mimics whole-body SMA mouse models in NMJ morphology. In the electrophysiological test, the SMAΔ7 mutant exhibited reduced quantal content, readily releasable pool, and vesicle release probability (<xref ref-type="bibr" rid="bib63">Torres-Benito et al., 2011</xref>). In our study, we did not directly assess the readily releasable pool in <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant by stimulus train of electrophysiological recording but instead showed reduced quantal content and normal vesicle release probability. In previous studies, it was theorized that the decrease in quantal contents in SMAΔ7 mutants resulted from decreased synaptic vesicle density at nerve terminals caused by motor neuron defects and abnormal axonal transport (<xref ref-type="bibr" rid="bib12">Dale et al., 2011</xref>; <xref ref-type="bibr" rid="bib34">Kong et al., 2009</xref>). However, we found that synaptic vesicle density was increased in the <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant with SMN-sufficient motor neurons. It is possible that the alteration of active zones, which were also altered in the SMA motor terminals (<xref ref-type="bibr" rid="bib34">Kong et al., 2009</xref>), contributed to the reduction in synaptic vesicle fusion and the decreased quantal contents. Indeed, nerve terminal detachment in <italic>SMN2</italic> 1-copy mutant mice was also found in active zone complex protein integrin-α3 knockout mice (<xref ref-type="bibr" rid="bib58">Ross et al., 2017</xref>). Based on the rescue data of transplanted healthy FAPs, we can report that FAP-specific SMN depletion is involved in NMJ pathology of SMA.</p><p>Second, we demonstrated that skeletal growth defects, a phenotype observed in SMA (<xref ref-type="bibr" rid="bib30">Khatri et al., 2008</xref>; <xref ref-type="bibr" rid="bib66">Vai et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Wasserman et al., 2017</xref>; <xref ref-type="bibr" rid="bib3">Baranello et al., 2019</xref>; <xref ref-type="bibr" rid="bib21">Hensel et al., 2020</xref>), are a cell-autonomous pathological effect of the depletion of SMN in bone-forming cells. We observed reduced bone size and volume in juvenile <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mutant. Depletion of SMN in chondrocytes showed growth plate homeostasis problems with chondrocyte-secreted IGF defects. However, our skeletal study has a limitation in that we did not assess potential impairment of endochondral ossification during embryonic development. It may be necessary to further evaluate the embryonic period in addition to the postnatal growth plate defects observed in our study, as cells of the <italic>Prrx1</italic>-lineage are involved in mesenchymal condensation and chondrocyte differentiation during embryonic endochondral ossification (<xref ref-type="bibr" rid="bib19">Hallett et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Racine and Serrat, 2020</xref>). Previous studies have reported that <italic>IGF1</italic> overexpression improves biochemical and behavioral manifestations in SMA mice, suggesting potential therapies for SMA (<xref ref-type="bibr" rid="bib5">Bosch-Marcé et al., 2011</xref>; <xref ref-type="bibr" rid="bib64">Tsai et al., 2014</xref>). Our study showed that these IGF therapies for SMA could be one to consider for treating bone growth abnormalities. In addition, the skeletal growth defect may affect physiologic muscle atrophy through imbalanced muscle contraction and reduced tension. This physiologic atrophy may be part of SMA-associated muscle weakness independent of neurogenic atrophy.</p><p>Third, it was demonstrated that adequate levels of SMN protein are essential for MPCs to contribute to limb neuromusculoskeletal development. The mutants with only 1 copy of <italic>SMN2</italic> exhibit problematic symptoms observed in both SMA patients and mouse models, while <italic>SMN2</italic> 2-copy mutants display a typical phenotype in bone and NMJ. The lack of SMN protein in MPCs by insufficient <italic>SMN2</italic> copies, similar to the deficiency seen in severe SMA, is responsible for the onset of SMA pathology. Thus, we propose that restoration of deficient SMN in MPCs is crucial for rehabilitating their function. Based on these discoveries, SMN replenishment treatments for MPCs, specifically FAPs, and chondrocytes, are necessary to provide a complete solution for neuromusculoskeletal defects in severe SMA patients.</p><p>The initial focus for the treatment of SMA was on motor neurons located in the spinal cord, and pharmaceuticals were created to address the deficiency of SMN in these neurons (<xref ref-type="bibr" rid="bib42">Mercuri et al., 2020</xref>). For example, intrathecal injections of Spinraza can efficiently boost SMN in the CNS, including the spinal cord (<xref ref-type="bibr" rid="bib53">Passini et al., 2011</xref>; <xref ref-type="bibr" rid="bib8">Claborn et al., 2019</xref>). However, Spinraza does not address the lack of SMN in peripheral tissues, including mesenchymal cells, highlighted in recent studies. The drug Zolgensma, which employs AAV9 to express SMN through systemic delivery, appears to resolve this issue (<xref ref-type="bibr" rid="bib16">Foust et al., 2009</xref>; <xref ref-type="bibr" rid="bib67">Valori et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Mattar et al., 2013</xref>). Nevertheless, a prior study indicates that chondrocytes within the growth plate and articular cartilage do not get infected with AAV9 (<xref ref-type="bibr" rid="bib76">Yang et al., 2019</xref>). Furthermore, it is well established that DNA vectors delivered via AAV9 undergo dilution during cell proliferation (<xref ref-type="bibr" rid="bib54">Penaud-Budloo et al., 2008</xref>; <xref ref-type="bibr" rid="bib10">Colella et al., 2018</xref>; <xref ref-type="bibr" rid="bib68">Van Alstyne et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Heller et al., 2021</xref>). Given the infection issue and the dilution issue by the active cell population changes of chondrocytes and FAPs during postnatal development (<xref ref-type="bibr" rid="bib55">Petrany et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Bachman and Chakkalakal, 2022</xref>), SMN supplementation through Zolgensma alone would not be sufficient for severe SMA patients. Thus, there is an urgent need to research and develop therapeutic strategies that target mesenchymal progenitors.</p><p>While this study is the first to demonstrate the impact of SMN depletion in FAPs on the NMJ development, it does not elucidate the specific mechanism by which FAPs influence the NMJ. Our study observed NMJ recovery in the muscles transplanted with healthy FAPs, but not in the contralateral muscles, indicating that FAPs are likely involved in NMJ development through juxtacrine or paracrine signaling. Since FAPs interact with surrounding tissues through a variety of signaling factors, such as extracellular matrix (<xref ref-type="bibr" rid="bib11">Contreras et al., 2021</xref>; <xref ref-type="bibr" rid="bib60">Scott et al., 2019</xref>), Wnt-related protein (<xref ref-type="bibr" rid="bib38">Lukjanenko et al., 2019</xref>), and Bmp signaling protein (<xref ref-type="bibr" rid="bib65">Uezumi et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Camps et al., 2020</xref>), mis-splicing of the signaling factors due to SMN reduction could disturb the homeostasis of neighboring tissues (<xref ref-type="bibr" rid="bib79">Zhang et al., 2008</xref>). Furthermore, the <italic>Hsd11b1</italic>-positive subpopulation of FAPs associated with NMJ was discovered through single-cell RNA sequencing in a recent study (<xref ref-type="bibr" rid="bib35">Leinroth et al., 2022</xref>). This population is located adjacent to the NMJ and responds to denervation, indicating an increased possibility of interaction with the NMJ organization. Therefore, it is necessary to conduct additional investigations into the expression of various signaling factors by diverse FAP subpopulations in future studies.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Prrx1<sup>Cre</sup></italic></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Strain #: 005584;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:005584">IMSR_JAX:005584</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Smn1<sup>f7/+</sup></italic></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Strain #: 006138; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:006138">IMSR_JAX:006138</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Rosa26<sup>LSL-YFP/+</sup></italic></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Strain #: 006148; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:006148">IMSR_JAX:006148</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Rosa26<sup>LSL-tdTomato/+</sup></italic></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Strain #: 007914; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:007914">IMSR_JAX:007914</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>SMN2</italic><sup>+/+</sup>; <italic>Smn1</italic><sup>+/−</sup></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Strain #: 005024; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:005024">IMSR_JAX:005024</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Smn1<sup>+/−</sup>; SMN2<sup>+/+</sup>; SMNΔ7<sup>+/+</sup></italic></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Strain #: 005025; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:005025">IMSR_JAX:005025</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-SMN (Mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat. #: 610646;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_397973">AB_397973</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-alpha-tubulin (Rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat. #: ab176560; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2860019">AB_2860019</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Neurofilament M (Rabbit polyclonal)</td><td align="left" valign="bottom">Merckmillipore</td><td align="left" valign="bottom">Cat. #: ab1987; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_91201">AB_91201</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Synaptophysin 1 (Guinea pig polyclonal)</td><td align="left" valign="bottom">Synaptic Systems</td><td align="left" valign="bottom">Cat. #: 101 004; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1210382">AB_1210382</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-GFP (Chicken polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat. #: ab13970; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_300798">AB_300798</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Ki67 (Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat. #: ab15580; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_443209">AB_443209</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Itgb3 (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat. #: 13166; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2798136">AB_2798136</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-p-AKT(S473) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat. #: 4060; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2315049">AB_2315049</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-CD45-APC (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat. #: 103111; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312976">AB_312976</ext-link></td><td align="left" valign="bottom">FACS (3 µl per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-CD31-APC (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat. #: 102409; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312904">AB_312904</ext-link></td><td align="left" valign="bottom">FACS (3 µl per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Sca-1(Ly6a)-FITC (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat. #: 122507; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_756192">AB_756192</ext-link></td><td align="left" valign="bottom">FACS (3 µl per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Sca-1(Ly6a)-Pacific blue (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat. #: 108120; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493273">AB_493273</ext-link></td><td align="left" valign="bottom">FACS (3 µl per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Vcam1-Biotin (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat. #: 105703; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313204">AB_313204</ext-link></td><td align="left" valign="bottom">FACS (3 µl per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Rabbit IgG-HRP (Goat monoclonal)</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat. #: W4011; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_430833">AB_430833</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Mouse IgG-HRP (Goat monoclonal)</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat. #: W4021; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_430834">AB_430834</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Rabbit IgG-Alexa fluor 488 (Goat monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A11034; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2576217">AB_2576217</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Chicken IgY-Alexa fluor 488 (Goat monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A11039; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534096">AB_2534096</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Rabbit IgG-Alexa fluor Plus 647 (Goat monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A32733; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2633282">AB_2633282</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Guine pig IgG-Alexa fluor 405 (Goat monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat. #: ab175678; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2827755">AB_2827755</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">PE-Cy7-Streptavidin</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat. #: 405206</td><td align="left" valign="bottom">FACS (3 µl per test)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Alpha-bungarotoxin-Alexa fluor 555</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: B35451</td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Alpha-bungarotoxin-Alexa fluor 488</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: B13422</td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">μ-conotoxin GIIIB</td><td align="left" valign="bottom">Alomone</td><td align="left" valign="bottom">Cat. #: C-270</td><td align="left" valign="bottom">Electrophysiology (2.5 µM)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA protein assay kits</td><td align="left" valign="bottom">Thermo<break/>Fisher<break/>Scientific</td><td align="left" valign="bottom">Cat. #: C-23225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">AccuCT</td><td align="left" valign="bottom">PerkinElmer</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Microsoft Excel</td><td align="left" valign="bottom">Microsoft</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016137">SCR_016137</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Leica Application Suite X</td><td align="left" valign="bottom">Leica</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013673">SCR_013673</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom">Graphpad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">pClamp</td><td align="left" valign="bottom">Molecular devices</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_011323">SCR_011323</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008539">SCR_008539</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Gill No. 3 formula hematoxylin</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: GHS332</td><td align="left" valign="bottom">Hematoxylin staining solution (1×)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Eosin Y solution</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: HT110116</td><td align="left" valign="bottom">Eosin staining solution (1×)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Toluidine blue</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: 198161</td><td align="left" valign="bottom">Toluidine blue staining (1%)</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p><italic>Prrx1<sup>Cre</sup></italic> (stock 005584), <italic>Smn1<sup>f7/+</sup></italic> (stock 006138), <italic>Rosa26 <sup>LSL-YFP/+</sup></italic> (stock 006148), <italic>Rosa26 <sup>LSL-tdTomato/+</sup></italic> (stock 007914), <italic>SMN2</italic><sup>+/+</sup>, <italic>Smn1</italic><sup>+/−</sup> (stock 005024 – <italic>Smn1</italic> knockout and <italic>SMN2</italic> homologous transgenic mouse) and <italic>Smn1<sup>+/−</sup>; SMN2<sup>+/+</sup>; SMNΔ7<sup>+/+</sup></italic> (stock 005025 005024 – <italic>Smn1</italic> knockout and <italic>SMN2</italic>, <italic>SMNΔ7</italic> homologous transgenic mouse) mice were acquired from The Jackson Laboratory (Bar Harbor, ME, USA). <italic>SMN2</italic> 0-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice (<italic>Prrx1<sup>Cre</sup>; Smn1<sup>f7/f7</sup></italic>), <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice (<italic>Prrx1<sup>Cre</sup>; Smn1<sup>f7/f7</sup>; SMN2<sup>+/0</sup> – SMN2</italic> heterologous allele), and <italic>SMN2</italic> 2-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice (<italic>Prrx1<sup>Cre</sup>; Smn1<sup>f7/f7</sup>; SMN2<sup>+/+</sup> – SMN2</italic> homologous allele) were generated by crossing <italic>Prrx1<sup>Cre</sup></italic> mice with <italic>Smn1<sup>f7/+</sup></italic> and <italic>Smn1<sup>+/−</sup>; SMN2<sup>+/+</sup></italic>mice. To utilize FAPs transplantation, we generated <italic>Prrx1<sup>Cre</sup>; Rosa26 <sup>LSL-YFP/+</sup></italic> mice and <italic>Prrx1<sup>Cre</sup>; Rosa26 <sup>LSL-tdTomato/+</sup></italic> mice by breeding <italic>Prrx1<sup>Cre</sup></italic> with <italic>Rosa26 <sup>LSL-YFP/+</sup></italic> and <italic>Rosa26 <sup>LSL-tdTomato/+</sup></italic> mice, respectively. To avoid deletion of the floxed allele by <italic>Prrx1<sup>Cre</sup></italic> expression in female germline, we bred females without <italic>Prrx1<sup>Cre</sup></italic> line to <italic>Prrx1<sup>Cre</sup></italic> transgenic males. SMAΔ7 mutants (<italic>Smn1<sup>−/−</sup>; SMN2<sup>+/+</sup>; SMNΔ7<sup>+/+</sup></italic>) were produced by mating <italic>Smn1<sup>+/−</sup>; SMN2<sup>+/+</sup>; SMNΔ7<sup>+/+</sup></italic> mice. Both male and female mice were used in the experiments, and no sex-specific differences were observed. Control littermates lacking <italic>Prrx1<sup>Cre</sup></italic> were utilized for analysis. All mouse lines were housed under controlled conditions with specific pathogen free and handled according to the guidelines of the Seoul National University Institutional Animal Care and Use Committee (Protocol number: SNU-210313-1).</p></sec><sec id="s4-2"><title>Micro-CT</title><p>The femurs from three groups – control, <italic>SMN2</italic> 2-copy <italic>Smn1<sup>ΔMPC</sup></italic>, and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at postnatal day 14 (P14) – were isolated and cleaned of muscles and skin. Subsequently, the femurs were preserved in 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) overnight at 4°C before micro-CT. The femurs were then imaged through a Quantum GX II micro-CT imaging system (PerkinElmer, Hopkinton, MA, USA). The X-ray source for scanning was set at 90 kV and 88 mA with a field of view of 10 mm (voxel size, 20 μm; scanning time, 14 min). The 3D imaging was viewed using the 3D Viewer software of the Quantum GX II. The size and volume of the femur bone were measured via AccuCT analysis software within the ossified diaphysis and metaphysis of the femur, excluding the epiphysis. BMD calibration was performed using a 4.5-mm BMD phantom and BMD measurements were taken at the center of the diaphysis.</p></sec><sec id="s4-3"><title>Histology</title><p>Alcian blue and alizarin red staining was performed on control and <italic>SMN2</italic> 0-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at E18.5 using a previously reported protocol (<xref ref-type="bibr" rid="bib50">Ovchinnikov, 2009</xref>). For H&amp;E and toluidine blue staining of the growth plate in the control and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice at P14, the femurs were fixed in 4% PFA for 24 hr, rinsed in running tap water for 24 hr, and incubated with 10% ethylenediaminetetraacetic acid (EDTA) (pH 7.4) at 4°C with shaking for 2–3 days. Subsequently, the samples were rinsed in running tap water for 24 hr and then dehydrated through ethanol/xylene and embedded in paraffin. The embedded samples were then sectioned to a thickness of 5 µm, rehydrated, and stained with Gill No. 3 formula hematoxylin and eosin Y (H&amp;E, Sigma-Aldrich, St. Louis, MO, USA) and toluidine blue (Sigma-Aldrich, St. Louis, MO, USA). Stained slides were analyzed using ×10 and ×20 objectives in the EVOS M7000 imaging system (Thermo Fisher Scientific, Waltham, MA, USA). The growth plate’s proliferative and hypertrophic zones were defined by their respective cell sizes.</p></sec><sec id="s4-4"><title>Hindlimb FAPs isolation</title><p>Isolation of limb muscle FAPs was performed according to a previously reported protocol (<xref ref-type="bibr" rid="bib31">Kim et al., 2020</xref>) with modifications. Limb muscles were dissected and mechanically dissociated in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone) containing 10% horse serum (Hyclone, Logan, UT, USA), collagenase II (800 units/ml; Worthington, Lakewood, NJ, USA), and dispase (1.1 units/ml; Thermo Fisher Scientific, Waltham, MA, USA) at 37°C for 40 min. Digested suspensions were subsequently triturated by sterilized syringes with 20 G 1/2 needle (BD Biosciences, Franklin Lakes, NJ, USA) and washed with DMEM to harvest mononuclear cells. Mononuclear cells were stained with corresponding antibodies. All antibodies used in fluorescence-activated cell sorting (FACS) analysis are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. To exclude dead cells, 7AAD (Sigma-Aldrich; St. Louis, MO, USA) was used. Stained cells were analyzed and 7AAD<sup>−</sup>Lin<sup>−</sup>Vcam<sup>−</sup>Sca1<sup>+</sup> (stem cell antigen 1; <italic>Ly6a</italic>) (FAPs) were isolated using FACS Aria III cell sorter (BD Biosciences) with four-way purity precision. For western blot, freshly isolated FAPs were cultured at 37°C in alpha-MEM (Hyclone) supplemented with Antibiotic–Antimycotic (anti–anti, Gibco) and 20% fetal bovine serum (FBS; Hyclone). For transplantation, YFP<sup>+</sup> FAPs and tdTomato<sup>+</sup> FAPs were isolated from postnatal day 10–21 <italic>Prrx1<sup>Cre</sup>; Rosa26 <sup>LSL-YFP/+</sup></italic> mice and <italic>Prrx1<sup>Cre</sup>; Rosa26 <sup>LSL-tdTomato/+</sup></italic> mice, respectively. Isotype control density plots were used as a reference for positive gating.</p></sec><sec id="s4-5"><title>Chondrocytes isolation</title><p>Isolation of chondrocytes followed a modified protocol previously published (<xref ref-type="bibr" rid="bib26">Jonason et al., 2015</xref>). Using blunt forceps, cartilage caps were removed from P21 mouse femoral heads and dissected into ~1 mm fragments in a Petri dish with 10× anti–anti in PBS. The cartilage fragments were washed twice with PBS and then incubated in 5 ml collagenase II solution (800 units/mL collagenase II in DMEM with anti–anti, sterilized by 0.2 µm filtration) in a 60 mm culture dish at 37°C in a 5% CO<sub>2</sub> incubator overnight. Chondrocytes were released by pipetting the remaining cartilage fragments 10 times and then filtering them through a 70-μm cell strainer to a 50-ml conical tube. The cells were then washed twice with PBS and pelleted by centrifugation at 500 × <italic>g</italic> for 5 min. Subsequently, the cells were cultured overnight at 37°C in a 5% CO<sub>2</sub> incubator, in complete culture medium (DMEM with 10% FBS and anti–anti) overnight at 37°C in a 5% CO<sub>2</sub> incubator.</p></sec><sec id="s4-6"><title>PCR reaction</title><p>To detect the presence of <italic>Smn1</italic> exon 7 floxed and deleted allele, 20 mg of each tissue were dissolved in direct PCR buffer (VIAGEN) with proteinase K overnight at 65°C. After inactivation at 95°C for 30 min, PCR was performed using previously reported primer sets to verify the existence of <italic>Cre</italic>, <italic>Smn1<sup>f7</sup></italic>, and <italic>Smn1<sup>Δ7</sup></italic> alleles (<xref ref-type="bibr" rid="bib17">Frugier et al., 2000</xref>). Primers are listed in .</p></sec><sec id="s4-7"><title>RNA extraction and measurement of mRNA expression</title><p>Total RNA was extracted from the brain, liver, spinal cord L4, tibialis anterior muscle, freshly isolated FAPs, and chondrocytes using a TRIzol Reagent (Life Technologies, Carlsbad, CA, USA) and analyzed by qRT-PCR. First-strand complementary DNA was synthesized from 1 μg of RNA using ReverTra Ace (Toyobo, Osaka, Japan) containing random oligomer according to the manufacturer’s instructions. qRT-PCR (QIAGEN) was performed with SYBR Green technology (SYBR Premix Ex Taq, QIAGEN) using specific primers against indicated genes. Relative mRNA levels were determined using the 2<sup>−ΔΔCt</sup> method and normalized to <italic>Gapdh</italic> (<xref ref-type="fig" rid="fig1">Figure 1H</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1K</xref>). Primers are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-8"><title>Western blot</title><p>Cultured FAPs at passage 3 were homogenized in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris–HCl, pH 7.5, 0.5% sodium dodecyl sulfate, 20 µg/ml aprotinin, 20 µg/ml leupeptin, 10 µg/ml phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 10 mM sodium fluoride, and 1 mM dithiothreitol). Cell lysates were centrifuged at 13,000 rpm for 15 min. Supernatants were collected and subjected to immunoblot. BCA protein assay (Thermo Fisher Scientific) was used for estimating total protein concentrations. Normalized total proteins were analyzed by electrophoresis in 10% polyacrylamide gels and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). Membranes were blocked in 5% skim milk (BD Biosciences) in tris-buffered saline (TBS) with 0.1% Tween-20 and incubated with primary antibodies overnight at 4°C. After incubation with the corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies, the membranes were developed using a Fusion solo chemiluminescence imaging system (Vilber, Marne-la-Vallée, France). α-Tubulin was used as a loading control. Band intensities were quantified using ImageJ software. Antibodies used in this study are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Primary and secondary antibodies were diluted 1:1000 and 1:10,000 with PBS containing 0.1% Tween-20 and 3% bovine serum albumin, respectively.</p></sec><sec id="s4-9"><title>FAPs transplantation</title><p>FAPs transplantation was performed according to a previously reported protocol (<xref ref-type="bibr" rid="bib31">Kim et al., 2020</xref>) with modifications. YFP<sup>+</sup> or tdTomato<sup>+</sup> FAPs (7AAD<sup>−</sup>Lin<sup>−</sup>Vcam<sup>−</sup>Sca1<sup>+</sup>) were isolated by FACS from the limb muscles of indicated mice. 1 × 10<sup>5</sup> FAPs were suspended in 0.1% gelatin (Sigma-Aldrich, St. Louis, MO, USA) in PBS and then transplanted into one side of the TA muscles of <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice. The contralateral muscle received an equivalent volume of 0.1% gelatin in PBS (Vehicle).</p></sec><sec id="s4-10"><title>Electrophysiology</title><p>The EDL muscle was dissected from control and <italic>SMN2</italic> 1-copy <italic>Smn1<sup>ΔMPC</sup></italic> mice, along with the peroneal nerve, and then pinned to a Sylgard-coated recording chamber. Intracellular recording was conducted in oxygenated Ringer’s solution, which comprised 138.8 mM NaCl, 4 mM KCl, 12 mM NaHCO<sub>3</sub>, 1 mM KH<sub>2</sub>PO<sub>4</sub>, 1 mM MgCl<sub>2</sub>, and 2 mM CaCl<sub>2</sub> with a pH of 7.4. Action potential of the muscle was prevented by preparing the muscle in 2.5 μM μ-conotoxin GIIIB (Alomone, Jerusalem, Israel) for 10 min beforehand. The recording was performed in toxin-free Ringer’s solution. mEPPs were recorded from a junction, followed by recordings of eEPPs by stimulating the attached peroneal nerve. The eEPPs were elicited using evoked stimulation. Paired-pulse stimulation (10-ms interstimulus interval) was utilized to assess synaptic transmission. The data were obtained and analyzed with Axoclamp 900A and Clampfit version 10.7 software.</p></sec><sec id="s4-11"><title>Transmission electron microscopy</title><p>NMJ TEM followed a modified protocol previously reported (<xref ref-type="bibr" rid="bib44">Modla et al., 2010</xref>). Mouse EDL muscle was swiftly excised and fixed in 4% PFA dissolved in Sorensen’s phosphate buffer (0.1 M, pH 7.2), followed by washing in 0.1 M phosphate buffer. The EDL was then gradually infiltrated on a rotator at room temperature with sucrose: 0.1 M phosphate buffer solutions of 30% and 50%, for 1 hr each, followed by an overnight incubation in 70% sucrose. Excess sucrose was then eliminated using filter paper, and the muscle was embedded in an optimal cutting temperature compound (O.C.T.; Sakura Fineteck, Torrance, CA, USA), followed by being frozen in a cryostat (Leica, Wetzlar, Germany). 10-µm-thick longitudinal sections were washed in PBS and treated with Alexa fluor 555-conjugated α-bungarotoxin (1:500, Invitrogen) for an hour. Imaging was conducted with the EVOS M7000 imaging system, and we selected four to five NMJ-rich regions for processing with TEM. The sections were fixed with 2% glutaraldehyde and 2% PFA in 0.1 M cacodylate buffer (pH 7.2) for 2 hr at room temperature, with an additional overnight incubation at 4°C. After washing with 0.1 M cacodylate buffer they were post-fixed with 1% osmium tetraoxide in 0.1 M cacodylate buffer (pH 7.2) for 2 hr at 4°C. The sections were then stained en bloc with 0.5% uranyl acetate overnight, washed with distilled water, and dehydrated using serial ethanol and propylene oxide. The sections were embedded in epoxy resin (Embed-812, Electron Microscopy Sciences) and detached from the slides by dipping them in liquid nitrogen. Ultra-thin sections (70 nm) were prepared with a diamond knife on an ultramicrotome (ULTRACUT UC7, Leica) and mounted on 100 mesh copper grids. Sections were stained with 2% uranyl acetate for 10 min and lead citrate for 3 min, then observed using a transmission electron microscope (80 kV, JEM1010, JEOL or 120 kV, Talos L120C, FEI). Synaptic vesicle density was quantified within a distance of 500 nm from the presynaptic membrane.</p></sec><sec id="s4-12"><title>Immunohistochemistry</title><p>For NMJ staining, freshly dissected TA muscles were fixed in 4% PFA for 30 min at room temperature. Subsequently, the muscles were cryoprotected in 30% sucrose overnight, embedded in O.C.T., snap-frozen in liquid nitrogen, and stored at −80°C prior to sectioning. Longitudinal 40-μm-thick sections were obtained from the embedded muscles using a cryostat. The sections were blocked for 2 hr at room temperature using 5% goat serum and 5% bovine serum albumin in PBS/0.4% Triton X-100. Then, the sections were incubated with primary antibodies in the blocking buffer for 2 days at 4°C. After washing the sections three times with PBS/0.4% Triton X-100, the sections were stained with secondary antibodies overnight at 4°C, and then incubated with Alexa fluor 488- or 555-conjugated α-bungarotoxin (1:500, Invitrogen) for 2 hr at room temperature (RT), washed three times with PBS/0.4% Triton X-100 and mounted in VECTASHIELD. Z-serial images were collected at ×40 with a Leica SP8 confocal laser scanning microscope. To analyze NMJ morphology, LasX software was used to obtain maximal projections. NF varicosity refers to the varicose NF end connected to the rest of the nerve terminal. To quantify NMJ size and synaptophysin coverage, the Btx area and synaptophysin area were measured by ImageJ analysis software.</p><p>For bone section staining, the 5-µm-thick bone sections were rehydrated and antigen retrieval was then performed in citrate buffer (10 mM citric acid, pH 6) at 95°C 20 min. The sections were blocked for 1 hr at room temperature using 5% goat serum and 5% bovine serum albumin in PBS/0.4% Triton X-100. Then, the sections were incubated with primary antibodies in the blocking buffer at 4°C overnight. After washing the sections three times with PBS/0.1% Triton X-100, the sections were stained with secondary antibodies for 1 hr at RT, washed and mounted. Imaging was conducted with the EVOS M7000 imaging system.</p></sec><sec id="s4-13"><title>Statistical analysis</title><p>Sample size determination was based on anticipated variability and effect size that was observed in the investigator’s lab for similar experiments. For quantification, individual performing the counts were blinded to sample identity and randomized. All statistical analyses were performed using GraphPad Prism 9 (GraphPad Software). For comparison of significant differences in multiple groups for normally distributed data, statistical analysis was performed by one- or two-way analysis of variance (ANOVA) followed by Tukey’s pairwise comparison post hoc test. For non-normally distributed data, Brown–Forsythe and Welch ANOVA followed by Games–Howell multiple comparisons test was used. For the comparison of two groups, Student’s unpaired <italic>t</italic>-test assuming a two-tailed distribution with Welch’s correction was used. Unless otherwise noted, all error bars represent standard error of the mean. The number of biological replicates and statistical analyses for each experiment were indicated in the figure legends. Independent experiments were performed at least in triplicates. p &lt; 0.05 was considered statistically significant at the 95% confidence level. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con7"><p>Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The care and treatment of animals in this study were approved by the Institutional Animal Care and Use Committee (IACUC) protocols (SNU-210313-1) of Seoul National University.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92731-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>A primer list of genomic PCR and qRT-PCR.</title></caption><media xlink:href="elife-92731-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files; source data files have been provided for Figure 2.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We express our gratitude to the Kong and Choi laboratory members for their valuable feedback during the project. This work was supported by the National Research Foundation of Korea (NRF-2022R1A2C3007621, NRF-2020R1A5A1018081, and NRF-2020R1A2C3011464).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachman</surname><given-names>JF</given-names></name><name><surname>Chakkalakal</surname><given-names>JV</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Insights into muscle stem cell dynamics during postnatal development</article-title><source>The FEBS Journal</source><volume>289</volume><fpage>2710</fpage><lpage>2722</lpage><pub-id pub-id-type="doi">10.1111/febs.15856</pub-id><pub-id pub-id-type="pmid">33811430</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>JP</given-names></name><name><surname>Robertson</surname><given-names>EJ</given-names></name><name><surname>Efstratiadis</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Role of insulin-like growth factors in embryonic and postnatal growth</article-title><source>Cell</source><volume>75</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">8402902</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baranello</surname><given-names>G</given-names></name><name><surname>Vai</surname><given-names>S</given-names></name><name><surname>Broggi</surname><given-names>F</given-names></name><name><surname>Masson</surname><given-names>R</given-names></name><name><surname>Arnoldi</surname><given-names>MT</given-names></name><name><surname>Zanin</surname><given-names>R</given-names></name><name><surname>Mastella</surname><given-names>C</given-names></name><name><surname>Bianchi</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evolution of bone mineral density, bone metabolism and fragility fractures in spinal muscular atrophy (SMA) types 2 and 3</article-title><source>Neuromuscular Disorders</source><volume>29</volume><fpage>525</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2019.06.001</pub-id><pub-id pub-id-type="pmid">31266719</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besse</surname><given-names>A</given-names></name><name><surname>Astord</surname><given-names>S</given-names></name><name><surname>Marais</surname><given-names>T</given-names></name><name><surname>Roda</surname><given-names>M</given-names></name><name><surname>Giroux</surname><given-names>B</given-names></name><name><surname>Lejeune</surname><given-names>FX</given-names></name><name><surname>Relaix</surname><given-names>F</given-names></name><name><surname>Smeriglio</surname><given-names>P</given-names></name><name><surname>Barkats</surname><given-names>M</given-names></name><name><surname>Biferi</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>AAV9-mediated expression of SMN restricted to neurons does not rescue the spinal muscular atrophy phenotype in mice</article-title><source>Molecular Therapy</source><volume>28</volume><fpage>1887</fpage><lpage>1901</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.05.011</pub-id><pub-id pub-id-type="pmid">32470325</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch-Marcé</surname><given-names>M</given-names></name><name><surname>Wee</surname><given-names>CD</given-names></name><name><surname>Martinez</surname><given-names>TL</given-names></name><name><surname>Lipkes</surname><given-names>CE</given-names></name><name><surname>Choe</surname><given-names>DW</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Van Meerbeke</surname><given-names>JP</given-names></name><name><surname>Musarò</surname><given-names>A</given-names></name><name><surname>Sumner</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Increased IGF-1 in muscle modulates the phenotype of severe SMA mice</article-title><source>Human Molecular Genetics</source><volume>20</volume><fpage>1844</fpage><lpage>1853</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr067</pub-id><pub-id pub-id-type="pmid">21325354</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burghes</surname><given-names>AHM</given-names></name><name><surname>Beattie</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?</article-title><source>Nature Reviews. Neuroscience</source><volume>10</volume><fpage>597</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1038/nrn2670</pub-id><pub-id pub-id-type="pmid">19584893</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camps</surname><given-names>J</given-names></name><name><surname>Breuls</surname><given-names>N</given-names></name><name><surname>Sifrim</surname><given-names>A</given-names></name><name><surname>Giarratana</surname><given-names>N</given-names></name><name><surname>Corvelyn</surname><given-names>M</given-names></name><name><surname>Danti</surname><given-names>L</given-names></name><name><surname>Grosemans</surname><given-names>H</given-names></name><name><surname>Vanuytven</surname><given-names>S</given-names></name><name><surname>Thiry</surname><given-names>I</given-names></name><name><surname>Belicchi</surname><given-names>M</given-names></name><name><surname>Meregalli</surname><given-names>M</given-names></name><name><surname>Platko</surname><given-names>K</given-names></name><name><surname>MacDonald</surname><given-names>ME</given-names></name><name><surname>Austin</surname><given-names>RC</given-names></name><name><surname>Gijsbers</surname><given-names>R</given-names></name><name><surname>Cossu</surname><given-names>G</given-names></name><name><surname>Torrente</surname><given-names>Y</given-names></name><name><surname>Voet</surname><given-names>T</given-names></name><name><surname>Sampaolesi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Interstitial cell remodeling promotes aberrant adipogenesis in dystrophic muscles</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107597</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107597</pub-id><pub-id pub-id-type="pmid">32375047</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claborn</surname><given-names>MK</given-names></name><name><surname>Stevens</surname><given-names>DL</given-names></name><name><surname>Walker</surname><given-names>CK</given-names></name><name><surname>Gildon</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nusinersen: a treatment for spinal muscular atrophy</article-title><source>The Annals of Pharmacotherapy</source><volume>53</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1177/1060028018789956</pub-id><pub-id pub-id-type="pmid">30008228</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colaianni</surname><given-names>G</given-names></name><name><surname>Cuscito</surname><given-names>C</given-names></name><name><surname>Mongelli</surname><given-names>T</given-names></name><name><surname>Pignataro</surname><given-names>P</given-names></name><name><surname>Buccoliero</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Sartini</surname><given-names>L</given-names></name><name><surname>Di Comite</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>G</given-names></name><name><surname>Di Benedetto</surname><given-names>A</given-names></name><name><surname>Brunetti</surname><given-names>G</given-names></name><name><surname>Yuen</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Reseland</surname><given-names>JE</given-names></name><name><surname>Colucci</surname><given-names>S</given-names></name><name><surname>New</surname><given-names>MI</given-names></name><name><surname>Zaidi</surname><given-names>M</given-names></name><name><surname>Cinti</surname><given-names>S</given-names></name><name><surname>Grano</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The myokine irisin increases cortical bone mass</article-title><source>PNAS</source><volume>112</volume><fpage>12157</fpage><lpage>12162</lpage><pub-id pub-id-type="doi">10.1073/pnas.1516622112</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colella</surname><given-names>P</given-names></name><name><surname>Ronzitti</surname><given-names>G</given-names></name><name><surname>Mingozzi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Emerging issues in AAV-mediated in vivo gene therapy</article-title><source>Molecular Therapy - Methods &amp; Clinical Development</source><volume>8</volume><fpage>87</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2017.11.007</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contreras</surname><given-names>O</given-names></name><name><surname>Rossi</surname><given-names>FMV</given-names></name><name><surname>Theret</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Origins, potency, and heterogeneity of skeletal muscle fibro-adipogenic progenitors-time for new definitions</article-title><source>Skeletal Muscle</source><volume>11</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1186/s13395-021-00265-6</pub-id><pub-id pub-id-type="pmid">34210364</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>JM</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Barry</surname><given-names>DM</given-names></name><name><surname>Garcia</surname><given-names>VB</given-names></name><name><surname>Rose</surname><given-names>FF</given-names></name><name><surname>Lorson</surname><given-names>CL</given-names></name><name><surname>Garcia</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The spinal muscular atrophy mouse model, SMAΔ7, displays altered axonal transport without global neurofilament alterations</article-title><source>Acta Neuropathologica</source><volume>122</volume><fpage>331</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0848-5</pub-id><pub-id pub-id-type="pmid">21681521</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Amicis</surname><given-names>R</given-names></name><name><surname>Baranello</surname><given-names>G</given-names></name><name><surname>Foppiani</surname><given-names>A</given-names></name><name><surname>Leone</surname><given-names>A</given-names></name><name><surname>Battezzati</surname><given-names>A</given-names></name><name><surname>Bedogni</surname><given-names>G</given-names></name><name><surname>Ravella</surname><given-names>S</given-names></name><name><surname>Giaquinto</surname><given-names>E</given-names></name><name><surname>Mastella</surname><given-names>C</given-names></name><name><surname>Agosto</surname><given-names>C</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>D’Amico</surname><given-names>A</given-names></name><name><surname>Pedemonte</surname><given-names>M</given-names></name><name><surname>Bruno</surname><given-names>C</given-names></name><name><surname>Wells</surname><given-names>JC</given-names></name><name><surname>Fewtrell</surname><given-names>M</given-names></name><name><surname>Bertoli</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Growth patterns in children with spinal muscular atrophy</article-title><source>Orphanet Journal of Rare Diseases</source><volume>16</volume><elocation-id>375</elocation-id><pub-id pub-id-type="doi">10.1186/s13023-021-02015-9</pub-id><pub-id pub-id-type="pmid">34481516</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deguise</surname><given-names>M</given-names></name><name><surname>Pileggi</surname><given-names>C</given-names></name><name><surname>Repentigny</surname><given-names>YD</given-names></name><name><surname>Beauvais</surname><given-names>A</given-names></name><name><surname>Tierney</surname><given-names>A</given-names></name><name><surname>Chehade</surname><given-names>L</given-names></name><name><surname>Michaud</surname><given-names>J</given-names></name><name><surname>Llavero-hurtado</surname><given-names>M</given-names></name><name><surname>Lamont</surname><given-names>D</given-names></name><name><surname>Atrih</surname><given-names>A</given-names></name><name><surname>Wishart</surname><given-names>TM</given-names></name><name><surname>Gillingwater</surname><given-names>TH</given-names></name><name><surname>Schneider</surname><given-names>BL</given-names></name><name><surname>Harper</surname><given-names>M</given-names></name><name><surname>Parson</surname><given-names>SH</given-names></name><name><surname>Kothary</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SMN depleted mice offer a robust and rapid onset model of nonalcoholic fatty liver disease</article-title><source>Cellular and Molecular Gastroenterology and Hepatology</source><volume>12</volume><fpage>354</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2021.01.019</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deschenes</surname><given-names>MR</given-names></name><name><surname>Tenny</surname><given-names>KA</given-names></name><name><surname>Wilson</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Increased and decreased activity elicits specific morphological adaptations of the neuromuscular junction</article-title><source>Neuroscience</source><volume>137</volume><fpage>1277</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2005.10.042</pub-id><pub-id pub-id-type="pmid">16359818</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foust</surname><given-names>KD</given-names></name><name><surname>Nurre</surname><given-names>E</given-names></name><name><surname>Montgomery</surname><given-names>CL</given-names></name><name><surname>Hernandez</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>CM</given-names></name><name><surname>Kaspar</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes</article-title><source>Nature Biotechnology</source><volume>27</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nbt.1515</pub-id><pub-id pub-id-type="pmid">19098898</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frugier</surname><given-names>T</given-names></name><name><surname>Tiziano</surname><given-names>FD</given-names></name><name><surname>Cifuentes-Diaz</surname><given-names>C</given-names></name><name><surname>Miniou</surname><given-names>P</given-names></name><name><surname>Roblot</surname><given-names>N</given-names></name><name><surname>Dierich</surname><given-names>A</given-names></name><name><surname>Le Meur</surname><given-names>M</given-names></name><name><surname>Melki</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy</article-title><source>Human Molecular Genetics</source><volume>9</volume><fpage>849</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1093/hmg/9.5.849</pub-id><pub-id pub-id-type="pmid">10749994</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govoni</surname><given-names>KE</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Chung</surname><given-names>YS</given-names></name><name><surname>Behringer</surname><given-names>RR</given-names></name><name><surname>Wergedal</surname><given-names>JE</given-names></name><name><surname>Baylink</surname><given-names>DJ</given-names></name><name><surname>Mohan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Disruption of insulin-like growth factor-I expression in type IIalphaI collagen-expressing cells reduces bone length and width in mice</article-title><source>Physiological Genomics</source><volume>30</volume><fpage>354</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1152/physiolgenomics.00022.2007</pub-id><pub-id pub-id-type="pmid">17519362</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallett</surname><given-names>SA</given-names></name><name><surname>Ono</surname><given-names>W</given-names></name><name><surname>Ono</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Growth plate chondrocytes: skeletal development, growth and beyond</article-title><source>International Journal of Molecular Sciences</source><volume>20</volume><elocation-id>6009</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20236009</pub-id><pub-id pub-id-type="pmid">31795305</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heller</surname><given-names>GJ</given-names></name><name><surname>Marshall</surname><given-names>MS</given-names></name><name><surname>Issa</surname><given-names>Y</given-names></name><name><surname>Marshall</surname><given-names>JN</given-names></name><name><surname>Nguyen</surname><given-names>D</given-names></name><name><surname>Rue</surname><given-names>E</given-names></name><name><surname>Pathmasiri</surname><given-names>KC</given-names></name><name><surname>Domowicz</surname><given-names>MS</given-names></name><name><surname>van Breemen</surname><given-names>RB</given-names></name><name><surname>Tai</surname><given-names>LM</given-names></name><name><surname>Cologna</surname><given-names>SM</given-names></name><name><surname>Crocker</surname><given-names>SJ</given-names></name><name><surname>Givogri</surname><given-names>MI</given-names></name><name><surname>Sands</surname><given-names>MS</given-names></name><name><surname>Bongarzone</surname><given-names>ER</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease</article-title><source>Molecular Therapy</source><volume>29</volume><fpage>1883</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.01.026</pub-id><pub-id pub-id-type="pmid">33508430</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensel</surname><given-names>N</given-names></name><name><surname>Brickwedde</surname><given-names>H</given-names></name><name><surname>Tsaknakis</surname><given-names>K</given-names></name><name><surname>Grages</surname><given-names>A</given-names></name><name><surname>Braunschweig</surname><given-names>L</given-names></name><name><surname>Lüders</surname><given-names>KA</given-names></name><name><surname>Lorenz</surname><given-names>HM</given-names></name><name><surname>Lippross</surname><given-names>S</given-names></name><name><surname>Walter</surname><given-names>LM</given-names></name><name><surname>Tavassol</surname><given-names>F</given-names></name><name><surname>Lienenklaus</surname><given-names>S</given-names></name><name><surname>Neunaber</surname><given-names>C</given-names></name><name><surname>Claus</surname><given-names>P</given-names></name><name><surname>Hell</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Altered bone development with impaired cartilage formation precedes neuromuscular symptoms in spinal muscular atrophy</article-title><source>Human Molecular Genetics</source><volume>29</volume><fpage>2662</fpage><lpage>2673</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddaa145</pub-id><pub-id pub-id-type="pmid">32644125</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoxha</surname><given-names>R</given-names></name><name><surname>Islami</surname><given-names>H</given-names></name><name><surname>Qorraj-Bytyqi</surname><given-names>H</given-names></name><name><surname>Thaçi</surname><given-names>S</given-names></name><name><surname>Bahtiri</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Relationship of weight and body mass index with bone mineral density in adult men from kosovo</article-title><source>Materia Socio-Medica</source><volume>26</volume><fpage>306</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.5455/msm.2014.26.306-308</pub-id><pub-id pub-id-type="pmid">25568627</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>Y</given-names></name><name><surname>Sahashi</surname><given-names>K</given-names></name><name><surname>Rigo</surname><given-names>F</given-names></name><name><surname>Hung</surname><given-names>G</given-names></name><name><surname>Horev</surname><given-names>G</given-names></name><name><surname>Bennett</surname><given-names>CF</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model</article-title><source>Nature</source><volume>478</volume><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/nature10485</pub-id><pub-id pub-id-type="pmid">21979052</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>YH</given-names></name><name><surname>Sahashi</surname><given-names>K</given-names></name><name><surname>Rigo</surname><given-names>F</given-names></name><name><surname>Bennett</surname><given-names>CF</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models</article-title><source>Genes &amp; Development</source><volume>29</volume><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1101/gad.256644.114</pub-id><pub-id pub-id-type="pmid">25583329</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ike</surname><given-names>H</given-names></name><name><surname>Inaba</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Yukizawa</surname><given-names>Y</given-names></name><name><surname>Aoki</surname><given-names>C</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Comparison between mechanical stress and bone mineral density in the femur after total hip arthroplasty by using subject-specific finite element analyses</article-title><source>Computer Methods in Biomechanics and Biomedical Engineering</source><volume>18</volume><fpage>1056</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1080/10255842.2013.869320</pub-id><pub-id pub-id-type="pmid">24661022</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jonason</surname><given-names>JH</given-names></name><name><surname>Hoak</surname><given-names>D</given-names></name><name><surname>O’Keefe</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><chapter-title>Primary murine growth plate and Articular Chondrocyte isolation and cell culture</chapter-title><person-group person-group-type="editor"><name><surname>Westendorf</surname><given-names>JJ</given-names></name><name><surname>van Wijnen</surname><given-names>AJ</given-names></name></person-group><source>Osteoporosis and Osteoarthritis</source><publisher-name>Humana Press</publisher-name><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-1619-1</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimian</surname><given-names>E</given-names></name><name><surname>Chagin</surname><given-names>AS</given-names></name><name><surname>Sävendahl</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Genetic regulation of the growth plate</article-title><source>Frontiers in Endocrinology</source><volume>2</volume><elocation-id>113</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2011.00113</pub-id><pub-id pub-id-type="pmid">22654844</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kariya</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>GH</given-names></name><name><surname>Maeno-Hikichi</surname><given-names>Y</given-names></name><name><surname>Leykekhman</surname><given-names>O</given-names></name><name><surname>Lutz</surname><given-names>C</given-names></name><name><surname>Arkovitz</surname><given-names>MS</given-names></name><name><surname>Landmesser</surname><given-names>LT</given-names></name><name><surname>Monani</surname><given-names>UR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy</article-title><source>Human Molecular Genetics</source><volume>17</volume><fpage>2552</fpage><lpage>2569</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddn156</pub-id><pub-id pub-id-type="pmid">18492800</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kariya</surname><given-names>S</given-names></name><name><surname>Obis</surname><given-names>T</given-names></name><name><surname>Garone</surname><given-names>C</given-names></name><name><surname>Akay</surname><given-names>T</given-names></name><name><surname>Sera</surname><given-names>F</given-names></name><name><surname>Iwata</surname><given-names>S</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Monani</surname><given-names>UR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation</article-title><source>The Journal of Clinical Investigation</source><volume>124</volume><fpage>785</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1172/JCI72017</pub-id><pub-id pub-id-type="pmid">24463453</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khatri</surname><given-names>IA</given-names></name><name><surname>Chaudhry</surname><given-names>US</given-names></name><name><surname>Seikaly</surname><given-names>MG</given-names></name><name><surname>Browne</surname><given-names>RH</given-names></name><name><surname>Iannaccone</surname><given-names>ST</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Low bone mineral density in spinal muscular atrophy</article-title><source>Journal of Clinical Neuromuscular Disease</source><volume>10</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1097/CND.0b013e318183e0fa</pub-id><pub-id pub-id-type="pmid">18772695</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Jha</surname><given-names>NN</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Faleiro</surname><given-names>MR</given-names></name><name><surname>Chiriboga</surname><given-names>CA</given-names></name><name><surname>Wei-Lapierre</surname><given-names>L</given-names></name><name><surname>Dirksen</surname><given-names>RT</given-names></name><name><surname>Ko</surname><given-names>CP</given-names></name><name><surname>Monani</surname><given-names>UR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>1271</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1172/JCI131989</pub-id><pub-id pub-id-type="pmid">32039917</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kang</surname><given-names>JS</given-names></name><name><surname>Yoo</surname><given-names>K</given-names></name><name><surname>Jeong</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Rhee</surname><given-names>J</given-names></name><name><surname>Jeon</surname><given-names>S</given-names></name><name><surname>Jo</surname><given-names>YW</given-names></name><name><surname>Hann</surname><given-names>SH</given-names></name><name><surname>Seo</surname><given-names>M</given-names></name><name><surname>Moon</surname><given-names>S</given-names></name><name><surname>Um</surname><given-names>SJ</given-names></name><name><surname>Seong</surname><given-names>RH</given-names></name><name><surname>Kong</surname><given-names>YY</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Bap1/SMN axis in Dpp4+ skeletal muscle mesenchymal cells regulates the neuromuscular system</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>e158380</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.158380</pub-id><pub-id pub-id-type="pmid">35603786</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kipoğlu</surname><given-names>O</given-names></name><name><surname>Karakılıç Özturan</surname><given-names>E</given-names></name><name><surname>Coşkun</surname><given-names>O</given-names></name><name><surname>Öztürk</surname><given-names>A</given-names></name><name><surname>Pembegül Yıldız</surname><given-names>E</given-names></name><name><surname>Baş</surname><given-names>F</given-names></name><name><surname>Aydınlı</surname><given-names>N</given-names></name><name><surname>Çalışkan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bone health and growth in spinal muscular atrophy type 2 and 3</article-title><source>Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi</source><volume>01</volume><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.26650/IUITFD.884235</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Choe</surname><given-names>DW</given-names></name><name><surname>Polley</surname><given-names>M</given-names></name><name><surname>Burnett</surname><given-names>BG</given-names></name><name><surname>Bosch-Marcé</surname><given-names>M</given-names></name><name><surname>Griffin</surname><given-names>JW</given-names></name><name><surname>Rich</surname><given-names>MM</given-names></name><name><surname>Sumner</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice</article-title><source>The Journal of Neuroscience</source><volume>29</volume><fpage>842</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4434-08.2009</pub-id><pub-id pub-id-type="pmid">19158308</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leinroth</surname><given-names>AP</given-names></name><name><surname>Mirando</surname><given-names>AJ</given-names></name><name><surname>Rouse</surname><given-names>D</given-names></name><name><surname>Kobayahsi</surname><given-names>Y</given-names></name><name><surname>Tata</surname><given-names>PR</given-names></name><name><surname>Rueckert</surname><given-names>HE</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Long</surname><given-names>JT</given-names></name><name><surname>Chakkalakal</surname><given-names>JV</given-names></name><name><surname>Hilton</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Identification of distinct non-myogenic skeletal-muscle-resident mesenchymal cell populations</article-title><source>Cell Reports</source><volume>39</volume><elocation-id>110785</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110785</pub-id><pub-id pub-id-type="pmid">35545045</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>KKY</given-names></name><name><surname>Lin</surname><given-names>MY</given-names></name><name><surname>Zingg</surname><given-names>B</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Ko</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e15457</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0015457</pub-id><pub-id pub-id-type="pmid">21085654</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>JF</given-names></name><name><surname>Nagy</surname><given-names>A</given-names></name><name><surname>Lobe</surname><given-names>C</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name><name><surname>Tabin</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer</article-title><source>Genesis</source><volume>33</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1002/gene.10092</pub-id><pub-id pub-id-type="pmid">12112875</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukjanenko</surname><given-names>L</given-names></name><name><surname>Karaz</surname><given-names>S</given-names></name><name><surname>Stuelsatz</surname><given-names>P</given-names></name><name><surname>Gurriaran-Rodriguez</surname><given-names>U</given-names></name><name><surname>Michaud</surname><given-names>J</given-names></name><name><surname>Dammone</surname><given-names>G</given-names></name><name><surname>Sizzano</surname><given-names>F</given-names></name><name><surname>Mashinchian</surname><given-names>O</given-names></name><name><surname>Ancel</surname><given-names>S</given-names></name><name><surname>Migliavacca</surname><given-names>E</given-names></name><name><surname>Liot</surname><given-names>S</given-names></name><name><surname>Jacot</surname><given-names>G</given-names></name><name><surname>Metairon</surname><given-names>S</given-names></name><name><surname>Raymond</surname><given-names>F</given-names></name><name><surname>Descombes</surname><given-names>P</given-names></name><name><surname>Palini</surname><given-names>A</given-names></name><name><surname>Chazaud</surname><given-names>B</given-names></name><name><surname>Rudnicki</surname><given-names>MA</given-names></name><name><surname>Bentzinger</surname><given-names>CF</given-names></name><name><surname>Feige</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Aging disrupts muscle stem cell function by impairing matricellular WISP1 Secretion from fibro-adipogenic progenitors</article-title><source>Cell Stem Cell</source><volume>24</volume><fpage>433</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.12.014</pub-id><pub-id pub-id-type="pmid">30686765</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>TL</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Osborne</surname><given-names>MA</given-names></name><name><surname>Crowder</surname><given-names>ME</given-names></name><name><surname>Van Meerbeke</surname><given-names>JP</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Wooley</surname><given-names>J</given-names></name><name><surname>Goldhamer</surname><given-names>DJ</given-names></name><name><surname>Lutz</surname><given-names>CM</given-names></name><name><surname>Rich</surname><given-names>MM</given-names></name><name><surname>Sumner</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>8703</fpage><lpage>8715</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0204-12.2012</pub-id><pub-id pub-id-type="pmid">22723710</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattar</surname><given-names>CN</given-names></name><name><surname>Waddington</surname><given-names>SN</given-names></name><name><surname>Biswas</surname><given-names>A</given-names></name><name><surname>Johana</surname><given-names>N</given-names></name><name><surname>Ng</surname><given-names>XW</given-names></name><name><surname>Fisk</surname><given-names>AS</given-names></name><name><surname>Fisk</surname><given-names>NM</given-names></name><name><surname>Tan</surname><given-names>LG</given-names></name><name><surname>Rahim</surname><given-names>AA</given-names></name><name><surname>Buckley</surname><given-names>SMK</given-names></name><name><surname>Tan</surname><given-names>MH</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Choolani</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>JKY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems</article-title><source>Gene Therapy</source><volume>20</volume><fpage>69</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/gt.2011.216</pub-id><pub-id pub-id-type="pmid">22278413</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGovern</surname><given-names>VL</given-names></name><name><surname>Iyer</surname><given-names>CC</given-names></name><name><surname>Arnold</surname><given-names>WD</given-names></name><name><surname>Gombash</surname><given-names>SE</given-names></name><name><surname>Zaworski</surname><given-names>PG</given-names></name><name><surname>Blatnik</surname><given-names>AJ</given-names></name><name><surname>Foust</surname><given-names>KD</given-names></name><name><surname>Burghes</surname><given-names>AHM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SMN expression is required in motor neurons to rescue electrophysiological deficits in the SMNΔ7 mouse model of SMA</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>5524</fpage><lpage>5541</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv283</pub-id><pub-id pub-id-type="pmid">26206889</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercuri</surname><given-names>E</given-names></name><name><surname>Pera</surname><given-names>MC</given-names></name><name><surname>Scoto</surname><given-names>M</given-names></name><name><surname>Finkel</surname><given-names>R</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Spinal muscular atrophy - insights and challenges in the treatment era</article-title><source>Nature Reviews. Neurology</source><volume>16</volume><fpage>706</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1038/s41582-020-00413-4</pub-id><pub-id pub-id-type="pmid">33057172</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercuri</surname><given-names>E</given-names></name><name><surname>Sumner</surname><given-names>CJ</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>Darras</surname><given-names>BT</given-names></name><name><surname>Finkel</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Spinal muscular atrophy</article-title><source>Nature Reviews. Disease Primers</source><volume>8</volume><pub-id pub-id-type="doi">10.1038/s41572-022-00380-8</pub-id><pub-id pub-id-type="pmid">35927425</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modla</surname><given-names>S</given-names></name><name><surname>Mendonca</surname><given-names>J</given-names></name><name><surname>Czymmek</surname><given-names>KJ</given-names></name><name><surname>Akins</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Identification of neuromuscular junctions by correlative confocal and transmission electron microscopy</article-title><source>Journal of Neuroscience Methods</source><volume>191</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.jneumeth.2010.06.015</pub-id><pub-id pub-id-type="pmid">20600319</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monani</surname><given-names>UR</given-names></name><name><surname>Sendtner</surname><given-names>M</given-names></name><name><surname>Coovert</surname><given-names>DD</given-names></name><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Andreassi</surname><given-names>C</given-names></name><name><surname>Le</surname><given-names>TT</given-names></name><name><surname>Jablonka</surname><given-names>S</given-names></name><name><surname>Schrank</surname><given-names>B</given-names></name><name><surname>Rossoll</surname><given-names>W</given-names></name><name><surname>Prior</surname><given-names>TW</given-names></name><name><surname>Morris</surname><given-names>GE</given-names></name><name><surname>Burghes</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy</article-title><source>Human Molecular Genetics</source><volume>9</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1093/hmg/9.3.333</pub-id><pub-id pub-id-type="pmid">10655541</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monani</surname><given-names>UR</given-names></name><name><surname>Pastore</surname><given-names>MT</given-names></name><name><surname>Gavrilina</surname><given-names>TO</given-names></name><name><surname>Jablonka</surname><given-names>S</given-names></name><name><surname>Le</surname><given-names>TT</given-names></name><name><surname>Andreassi</surname><given-names>C</given-names></name><name><surname>DiCocco</surname><given-names>JM</given-names></name><name><surname>Lorson</surname><given-names>C</given-names></name><name><surname>Androphy</surname><given-names>EJ</given-names></name><name><surname>Sendtner</surname><given-names>M</given-names></name><name><surname>Podell</surname><given-names>M</given-names></name><name><surname>Burghes</surname><given-names>AHM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy</article-title><source>The Journal of Cell Biology</source><volume>160</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1083/jcb.200208079</pub-id><pub-id pub-id-type="pmid">12515823</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdocca</surname><given-names>M</given-names></name><name><surname>Malgieri</surname><given-names>A</given-names></name><name><surname>Luchetti</surname><given-names>A</given-names></name><name><surname>Saieva</surname><given-names>L</given-names></name><name><surname>Dobrowolny</surname><given-names>G</given-names></name><name><surname>de Leonibus</surname><given-names>E</given-names></name><name><surname>Filareto</surname><given-names>A</given-names></name><name><surname>Quitadamo</surname><given-names>MC</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name><name><surname>Musarò</surname><given-names>A</given-names></name><name><surname>Sangiuolo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of spinal muscular atrophy</article-title><source>Molecular Medicine</source><volume>18</volume><fpage>1076</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.2119/molmed.2012.00056</pub-id><pub-id pub-id-type="pmid">22669476</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassari</surname><given-names>S</given-names></name><name><surname>Duprez</surname><given-names>D</given-names></name><name><surname>Fournier-Thibault</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Non-myogenic contribution to muscle development and homeostasis: the role of connective tissues</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>5</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2017.00022</pub-id><pub-id pub-id-type="pmid">28386539</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oichi</surname><given-names>T</given-names></name><name><surname>Kodama</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Imamura Kawasawa</surname><given-names>Y</given-names></name><name><surname>Usami</surname><given-names>Y</given-names></name><name><surname>Oshima</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Iwamoto</surname><given-names>M</given-names></name><name><surname>Otsuru</surname><given-names>S</given-names></name><name><surname>Enomoto-Iwamoto</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Nutrient-regulated dynamics of chondroprogenitors in the postnatal murine growth plate</article-title><source>Bone Research</source><volume>11</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.1038/s41413-023-00258-9</pub-id><pub-id pub-id-type="pmid">37080994</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ovchinnikov</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Alcian blue/alizarin red staining of cartilage and bone in mouse</article-title><source>Cold Spring Harbor Protocols</source><volume>2009</volume><elocation-id>pdb.prot5170</elocation-id><pub-id pub-id-type="doi">10.1101/pdb.prot5170</pub-id><pub-id pub-id-type="pmid">20147105</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>GH</given-names></name><name><surname>Maeno-Hikichi</surname><given-names>Y</given-names></name><name><surname>Awano</surname><given-names>T</given-names></name><name><surname>Landmesser</surname><given-names>LT</given-names></name><name><surname>Monani</surname><given-names>UR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene</article-title><source>The Journal of Neuroscience</source><volume>30</volume><fpage>12005</fpage><lpage>12019</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2208-10.2010</pub-id><pub-id pub-id-type="pmid">20826664</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passini</surname><given-names>MA</given-names></name><name><surname>Bu</surname><given-names>J</given-names></name><name><surname>Roskelley</surname><given-names>EM</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Sardi</surname><given-names>SP</given-names></name><name><surname>O’Riordan</surname><given-names>CR</given-names></name><name><surname>Klinger</surname><given-names>KW</given-names></name><name><surname>Shihabuddin</surname><given-names>LS</given-names></name><name><surname>Cheng</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy</article-title><source>The Journal of Clinical Investigation</source><volume>120</volume><fpage>1253</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1172/JCI41615</pub-id><pub-id pub-id-type="pmid">20234094</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passini</surname><given-names>MA</given-names></name><name><surname>Bu</surname><given-names>J</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Kinnecom</surname><given-names>C</given-names></name><name><surname>Sardi</surname><given-names>SP</given-names></name><name><surname>Stanek</surname><given-names>LM</given-names></name><name><surname>Hua</surname><given-names>Y</given-names></name><name><surname>Rigo</surname><given-names>F</given-names></name><name><surname>Matson</surname><given-names>J</given-names></name><name><surname>Hung</surname><given-names>G</given-names></name><name><surname>Kaye</surname><given-names>EM</given-names></name><name><surname>Shihabuddin</surname><given-names>LS</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name><name><surname>Bennett</surname><given-names>CF</given-names></name><name><surname>Cheng</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy</article-title><source>Science Translational Medicine</source><volume>3</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3001777</pub-id><pub-id pub-id-type="pmid">21368223</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penaud-Budloo</surname><given-names>M</given-names></name><name><surname>Le Guiner</surname><given-names>C</given-names></name><name><surname>Nowrouzi</surname><given-names>A</given-names></name><name><surname>Toromanoff</surname><given-names>A</given-names></name><name><surname>Chérel</surname><given-names>Y</given-names></name><name><surname>Chenuaud</surname><given-names>P</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>von Kalle</surname><given-names>C</given-names></name><name><surname>Rolling</surname><given-names>F</given-names></name><name><surname>Moullier</surname><given-names>P</given-names></name><name><surname>Snyder</surname><given-names>RO</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle</article-title><source>Journal of Virology</source><volume>82</volume><fpage>7875</fpage><lpage>7885</lpage><pub-id pub-id-type="doi">10.1128/JVI.00649-08</pub-id><pub-id pub-id-type="pmid">18524821</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrany</surname><given-names>MJ</given-names></name><name><surname>Swoboda</surname><given-names>CO</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Chetal</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Weirauch</surname><given-names>MT</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><name><surname>Millay</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-nucleus RNA-seq identifies transcriptional heterogeneity in multinucleated skeletal myofibers</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>6374</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-20063-w</pub-id><pub-id pub-id-type="pmid">33311464</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Racine</surname><given-names>HL</given-names></name><name><surname>Serrat</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The actions of IGF-1 in the growth plate and its role in postnatal bone elongation</article-title><source>Current Osteoporosis Reports</source><volume>18</volume><fpage>210</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1007/s11914-020-00570-x</pub-id><pub-id pub-id-type="pmid">32415542</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname><given-names>SG</given-names></name><name><surname>Alawi</surname><given-names>KM</given-names></name><name><surname>Rodrigues</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Kusumbe</surname><given-names>AP</given-names></name><name><surname>Ramasamy</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Endothelial proteolytic activity and interaction with non-resorbing osteoclasts mediate bone elongation</article-title><source>Nature Cell Biology</source><volume>21</volume><fpage>430</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0304-7</pub-id><pub-id pub-id-type="pmid">30936475</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>JA</given-names></name><name><surname>Webster</surname><given-names>RG</given-names></name><name><surname>Lechertier</surname><given-names>T</given-names></name><name><surname>Reynolds</surname><given-names>LE</given-names></name><name><surname>Turmaine</surname><given-names>M</given-names></name><name><surname>Bencze</surname><given-names>M</given-names></name><name><surname>Jamshidi</surname><given-names>Y</given-names></name><name><surname>Cetin</surname><given-names>H</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>Beeson</surname><given-names>D</given-names></name><name><surname>Hodilvala-Dilke</surname><given-names>K</given-names></name><name><surname>Conti</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Multiple roles of integrin-α3 at the neuromuscular junction</article-title><source>Journal of Cell Science</source><volume>130</volume><fpage>1772</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1242/jcs.201103</pub-id><pub-id pub-id-type="pmid">28386022</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahashi</surname><given-names>K</given-names></name><name><surname>Ling</surname><given-names>KKY</given-names></name><name><surname>Hua</surname><given-names>Y</given-names></name><name><surname>Wilkinson</surname><given-names>JE</given-names></name><name><surname>Nomakuchi</surname><given-names>T</given-names></name><name><surname>Rigo</surname><given-names>F</given-names></name><name><surname>Hung</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>YP</given-names></name><name><surname>Lin</surname><given-names>RZ</given-names></name><name><surname>Ko</surname><given-names>CP</given-names></name><name><surname>Bennett</surname><given-names>CF</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pathological impact of SMN2 mis-splicing in adult SMA mice</article-title><source>EMBO Molecular Medicine</source><volume>5</volume><fpage>1586</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1002/emmm.201302567</pub-id><pub-id pub-id-type="pmid">24014320</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>RW</given-names></name><name><surname>Arostegui</surname><given-names>M</given-names></name><name><surname>Schweitzer</surname><given-names>R</given-names></name><name><surname>Rossi</surname><given-names>FMV</given-names></name><name><surname>Underhill</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hic1 defines quiescent mesenchymal progenitor subpopulations with distinct functions and fates in skeletal muscle regeneration</article-title><source>Cell Stem Cell</source><volume>25</volume><fpage>797</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.11.004</pub-id><pub-id pub-id-type="pmid">31809738</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The developmental basis of mesenchymal stem/stromal cells (MSCs)</article-title><source>BMC Developmental Biology</source><volume>15</volume><elocation-id>44</elocation-id><pub-id pub-id-type="doi">10.1186/s12861-015-0094-5</pub-id><pub-id pub-id-type="pmid">26589542</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pubertal growth and epiphyseal fusion</article-title><source>Annals of Pediatric Endocrinology &amp; Metabolism</source><volume>20</volume><fpage>8</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.6065/apem.2015.20.1.8</pub-id><pub-id pub-id-type="pmid">25883921</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Benito</surname><given-names>L</given-names></name><name><surname>Neher</surname><given-names>MF</given-names></name><name><surname>Cano</surname><given-names>R</given-names></name><name><surname>Ruiz</surname><given-names>R</given-names></name><name><surname>Tabares</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>SMN requirement for synaptic vesicle, active zone and microtubule postnatal organization in motor nerve terminals</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e26164</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0026164</pub-id><pub-id pub-id-type="pmid">22022549</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>LK</given-names></name><name><surname>Chen</surname><given-names>CL</given-names></name><name><surname>Ting</surname><given-names>CH</given-names></name><name><surname>Lin-Chao</surname><given-names>S</given-names></name><name><surname>Hwu</surname><given-names>WL</given-names></name><name><surname>Dodge</surname><given-names>JC</given-names></name><name><surname>Passini</surname><given-names>MA</given-names></name><name><surname>Cheng</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice</article-title><source>Molecular Therapy</source><volume>22</volume><fpage>1450</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1038/mt.2014.84</pub-id><pub-id pub-id-type="pmid">24814151</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uezumi</surname><given-names>A</given-names></name><name><surname>Ikemoto-Uezumi</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Kurosawa</surname><given-names>T</given-names></name><name><surname>Yoshimoto</surname><given-names>Y</given-names></name><name><surname>Nakatani</surname><given-names>M</given-names></name><name><surname>Hitachi</surname><given-names>K</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Wakatsuki</surname><given-names>S</given-names></name><name><surname>Araki</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Toyoda</surname><given-names>M</given-names></name><name><surname>Kanazawa</surname><given-names>N</given-names></name><name><surname>Nakazawa</surname><given-names>T</given-names></name><name><surname>Hino</surname><given-names>J</given-names></name><name><surname>Fukada</surname><given-names>SI</given-names></name><name><surname>Tsuchida</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mesenchymal Bmp3b expression maintains skeletal muscle integrity and decreases in age-related sarcopenia</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>e139617</elocation-id><pub-id pub-id-type="doi">10.1172/JCI139617</pub-id><pub-id pub-id-type="pmid">33170806</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vai</surname><given-names>S</given-names></name><name><surname>Bianchi</surname><given-names>ML</given-names></name><name><surname>Moroni</surname><given-names>I</given-names></name><name><surname>Mastella</surname><given-names>C</given-names></name><name><surname>Broggi</surname><given-names>F</given-names></name><name><surname>Morandi</surname><given-names>L</given-names></name><name><surname>Arnoldi</surname><given-names>MT</given-names></name><name><surname>Bussolino</surname><given-names>C</given-names></name><name><surname>Baranello</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bone and spinal muscular atrophy</article-title><source>Bone</source><volume>79</volume><fpage>116</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2015.05.039</pub-id><pub-id pub-id-type="pmid">26055105</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valori</surname><given-names>CF</given-names></name><name><surname>Ning</surname><given-names>K</given-names></name><name><surname>Wyles</surname><given-names>M</given-names></name><name><surname>Mead</surname><given-names>RJ</given-names></name><name><surname>Grierson</surname><given-names>AJ</given-names></name><name><surname>Shaw</surname><given-names>PJ</given-names></name><name><surname>Azzouz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy</article-title><source>Science Translational Medicine</source><volume>2</volume><elocation-id>35ra42</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3000830</pub-id><pub-id pub-id-type="pmid">20538619</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Alstyne</surname><given-names>M</given-names></name><name><surname>Tattoli</surname><given-names>I</given-names></name><name><surname>Delestrée</surname><given-names>N</given-names></name><name><surname>Recinos</surname><given-names>Y</given-names></name><name><surname>Workman</surname><given-names>E</given-names></name><name><surname>Shihabuddin</surname><given-names>LS</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Mentis</surname><given-names>GZ</given-names></name><name><surname>Pellizzoni</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit</article-title><source>Nature Neuroscience</source><volume>24</volume><fpage>930</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1038/s41593-021-00827-3</pub-id><pub-id pub-id-type="pmid">33795885</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Bondy</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy</article-title><source>FASEB Journal</source><volume>13</volume><fpage>1985</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1096/fasebj.13.14.1985</pub-id><pub-id pub-id-type="pmid">10544181</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Elalieh</surname><given-names>HZ</given-names></name><name><surname>Nakamura</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>MT</given-names></name><name><surname>Mackem</surname><given-names>S</given-names></name><name><surname>Clemens</surname><given-names>TL</given-names></name><name><surname>Bikle</surname><given-names>DD</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>IGF-1R signaling in chondrocytes modulates growth plate development by interacting with the PTHrP/Ihh pathway</article-title><source>Journal of Bone and Mineral Research</source><volume>26</volume><fpage>1437</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1002/jbmr.359</pub-id><pub-id pub-id-type="pmid">21312270</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasserman</surname><given-names>HM</given-names></name><name><surname>Hornung</surname><given-names>LN</given-names></name><name><surname>Stenger</surname><given-names>PJ</given-names></name><name><surname>Rutter</surname><given-names>MM</given-names></name><name><surname>Wong</surname><given-names>BL</given-names></name><name><surname>Rybalsky</surname><given-names>I</given-names></name><name><surname>Khoury</surname><given-names>JC</given-names></name><name><surname>Kalkwarf</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity</article-title><source>Neuromuscular Disorders</source><volume>27</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2017.01.019</pub-id><pub-id pub-id-type="pmid">28258940</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilk</surname><given-names>K</given-names></name><name><surname>Yeh</surname><given-names>SCA</given-names></name><name><surname>Mortensen</surname><given-names>LJ</given-names></name><name><surname>Ghaffarigarakani</surname><given-names>S</given-names></name><name><surname>Lombardo</surname><given-names>CM</given-names></name><name><surname>Bassir</surname><given-names>SH</given-names></name><name><surname>Aldawood</surname><given-names>ZA</given-names></name><name><surname>Lin</surname><given-names>CP</given-names></name><name><surname>Intini</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Postnatal calvarial skeletal stem cells expressing PRX1 reside exclusively in the calvarial sutures and are required for bone regeneration</article-title><source>Stem Cell Reports</source><volume>8</volume><fpage>933</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.03.002</pub-id><pub-id pub-id-type="pmid">28366454</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wosczyna</surname><given-names>MN</given-names></name><name><surname>Konishi</surname><given-names>CT</given-names></name><name><surname>Perez Carbajal</surname><given-names>EE</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Walsh</surname><given-names>RA</given-names></name><name><surname>Gan</surname><given-names>Q</given-names></name><name><surname>Wagner</surname><given-names>MW</given-names></name><name><surname>Rando</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mesenchymal stromal cells are required for regeneration and homeostatic maintenance of skeletal muscle</article-title><source>Cell Reports</source><volume>27</volume><fpage>2029</fpage><lpage>2035</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.04.074</pub-id><pub-id pub-id-type="pmid">31091443</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yakar</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>JL</given-names></name><name><surname>Stannard</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Accili</surname><given-names>D</given-names></name><name><surname>Sauer</surname><given-names>B</given-names></name><name><surname>LeRoith</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Normal growth and development in the absence of hepatic insulin-like growth factor I</article-title><source>PNAS</source><volume>96</volume><fpage>7324</fpage><lpage>7329</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.13.7324</pub-id><pub-id pub-id-type="pmid">10377413</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yakar</surname><given-names>S</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Beamer</surname><given-names>WG</given-names></name><name><surname>Ackert-Bicknell</surname><given-names>CL</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>JL</given-names></name><name><surname>Ooi</surname><given-names>GT</given-names></name><name><surname>Setser</surname><given-names>J</given-names></name><name><surname>Frystyk</surname><given-names>J</given-names></name><name><surname>Boisclair</surname><given-names>YR</given-names></name><name><surname>LeRoith</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Circulating levels of IGF-1 directly regulate bone growth and density</article-title><source>The Journal of Clinical Investigation</source><volume>110</volume><fpage>771</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1172/JCI15463</pub-id><pub-id pub-id-type="pmid">12235108</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YS</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Tai</surname><given-names>PWL</given-names></name><name><surname>Gravallese</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Shim</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2958</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10809-6</pub-id><pub-id pub-id-type="pmid">31273195</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yesbek Kaymaz</surname><given-names>A</given-names></name><name><surname>Bal</surname><given-names>A</given-names></name><name><surname>Bora-Tatar</surname><given-names>G</given-names></name><name><surname>Ozon</surname><given-names>A</given-names></name><name><surname>Alikasifoglu</surname><given-names>A</given-names></name><name><surname>Topaloglu</surname><given-names>H</given-names></name><name><surname>Erdem-Yurter</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Serum IGF1 and IGFBP3 levels in SMA patients</article-title><source>Neuromuscular Disorders</source><volume>26</volume><elocation-id>S105</elocation-id><pub-id pub-id-type="doi">10.1016/j.nmd.2016.06.075</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanetti</surname><given-names>G</given-names></name><name><surname>Negro</surname><given-names>S</given-names></name><name><surname>Megighian</surname><given-names>A</given-names></name><name><surname>Pirazzini</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Electrophysiological recordings of evoked end-plate potential on murine neuro-muscular synapse preparations</article-title><source>BIO-PROTOCOL</source><volume>8</volume><elocation-id>e2803</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.2803</pub-id><pub-id pub-id-type="pmid">34286022</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Lotti</surname><given-names>F</given-names></name><name><surname>Dittmar</surname><given-names>K</given-names></name><name><surname>Younis</surname><given-names>I</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Kasim</surname><given-names>M</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing</article-title><source>Cell</source><volume>133</volume><fpage>585</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.03.031</pub-id><pub-id pub-id-type="pmid">18485868</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92731.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ryu</surname><given-names>Vitaly</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> work by Hann et al. advances our understanding of the role of the survival motor neuron (SMN) protein in coordinating pathogenesis of the spinal muscular atrophy (SMA). The authors addressed many concerns raised by the reviewers, providing <bold>convincing</bold> evidence in terms of skeletal analyses not being able to satisfactorily elucidate SMN regulation of bone development.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92731.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The manuscript by Hann et. al examines the role of survival motor neuron protein (SMN) in lateral plate mesoderm-derived cells using the Prrx1Cre to elucidate how changing cell-specific SMN levels coordinate aspects of the spinal muscular atrophy (SMA) pathology. SMN has generally been studied in neuronal cells, and this is one of the first insights into non-neuronal cells that may contribute to SMA disease. The authors generated 3 mouse lines: a Prrx1;Smnf/f conditional null mouse, as well as, single and double copy Prrx1;Smnf/f;SMN2 mice carrying either one or two copies of a human SMN2 transgene. First, the bone development and growth of all three were assessed; the conditional null Smn mutation was lethal shortly after birth, while the SMN2 2-copy mutant did not exhibit bone growth phenotypes. Meanwhile, single-copy SMN2 mutant mice showed reduced size and shorter limbs with shorter proliferative and hypertrophic chondrocyte zones. The authors suggested that this was cell autonomous by assessing the expression of extrinsic factors known to modulate proliferation/differentiation of growth plate chondrocytes. After assessing bone phenotypes, the authors transitioned to the assessments of neuromuscular junction (NMJ) phenotypes, since there are documented neuromuscular impairments in SMA and the Prrx1Cre transgene is expressed in muscle-associated fibro-adipogenic progenitors (FAPs). Neonatal NMJ development was unchanged in mutant mice with two copies of SMN2 , but adult single-copy SMN2 mutant mice had abnormal NMJ morphology, altered presynaptic neurotransmission, and problematic nerve terminal structure. Finally, the authors sought to assess the ability to rescue NMJ phenotypes via FAP cell transplantation and showed wild-type FAPs were able to reduce pre/postsynaptic fragmentation and neurofilament varicosities.</p><p>Strengths:</p><p>The conditional genetic approaches are novel and interestingly demonstrate the potential for chondrocyte and fibro-adipogenic progenitor-specific contributions to the SMA pathology.</p><p>The characterizations of the neuromuscular and NMJ phenotypes are relatively strong.</p><p>The data strongly suggest a non-neuronal contribution to SMA, which indicates a need for further mechanistic (cellular and molecular) studies to better understand SMA.</p><p>Weaknesses:</p><p>The skeletal analyses are not rigorous and likely do not get to the core of how SMN regulates bone development.</p><p>The overall work is descriptive and lacks convincing mechanisms.</p><p>Additional experimentation is likely needed to fully justify the conclusions.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92731.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Sang-Hyeon et al. laid out a compelling rationale to explore the role of the SMN protein in mesenchymal cells, to determine whether SMN deficiency there could be a pathologic mechanism of SMA. They crossed Smnf7/f7 mice with Prrx1Cre mice to produce SmnΔMPC mice where exon 7 was specifically deleted and thus SMN protein was eliminated in limb mesenchymal progenitor cells (MPCs). To demonstrate gene dosage-dependence of phenotypes, SmnΔMPC mice were crossed with transgenic mice expressing human SMN2 to produce SmnΔMPC mice with different copies of SMN2 (0, 1, or 2). The paper provides genetic evidence that SMN in mesenchymal cells regulates the development of bones and neuromuscular junctions. Genetic data were convincing and revealed novel functions of SMN.</p><p>Strengths:</p><p>Overall, the paper provided genetic evidence that SMN deficiency in mesenchymal cells caused abnormalities in bones and NMJs, revealing novel functions of SMN and leading to future experiments. As far as genetics is concerned, the data were convincing (except for the rescue experiment, see below); the conclusions are important.</p><p>Weaknesses:</p><p>The paper seemed to be descriptive in nature and could be improved with more experiments to investigate underlying mechanisms. In addition, some data appeared to be contradicting or difficult to explain. The rescue data were not convincing.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92731.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>SMN expression in non-neuronal cells, particularly in limb mesenchymal progenitors is essential for the proper growth of chondrocytes and the formation of adult NMJ junctions.</p><p>Strengths:</p><p>The authors show copy numbers of smndelta7 in MPC influence NMJ structure.</p><p>Weaknesses:</p><p>Functional recovery by FAP transplantation is not complete. Mesenchymal progenitors are heterogeneous, and how heterogeneity influences this study is not clear. Part of the main findings to show the importance of SMN expression in non-neuronal cells is partly published by the same group (Kim et al., JCI Insight 2022). In the study, the authors used Dpp4(+) cells. The difference between the current study and the previous study is not so clear.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92731.3.sa4</article-id><title-group><article-title>Author Response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hann</surname><given-names>Sang-Hyeon</given-names></name><role specific-use="author">Author</role><aff><institution>Seoul National University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Seon-Yong</given-names></name><role specific-use="author">Author</role><aff><institution>Seoul National University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Ye Lynne</given-names></name><role specific-use="author">Author</role><aff><institution>Seoul National University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib><contrib contrib-type="author"><name><surname>Jo</surname><given-names>Young-Woo</given-names></name><role specific-use="author">Author</role><aff><institution>Seoul National University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Jong-Seol</given-names></name><role specific-use="author">Author</role><aff><institution>Seoul National University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Hyerim</given-names></name><role specific-use="author">Author</role><aff><institution>Seoul National University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Se-Young</given-names></name><role specific-use="author">Author</role><aff><institution>Seoul National University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib><contrib contrib-type="author"><name><surname>Kong</surname><given-names>Young-Yun</given-names></name><role specific-use="author">Author</role><aff><institution>Seoul National University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1</bold></p><p>Major comments:</p><p>1. The authors conclude that the bone growth defects are chondrocyte-specific, highlighting no changes in the IGF pathway. However, other bone cells such as mesenchymal progenitors, osteoblasts, osteocytes, and marrow stromal cells are also lateral plate mesoderm derived and likely have roles in the bone growth phenotypes (a). Additionally, while the size decrease of the proliferative zone was stated, no actual proliferation assays such as BrdU were conducted (b). With the elements being of such small size in the mutants, the defects are likely to be found at the earliest stages of limb development at E11.5-E13.5 and may be due to mesenchymal to chondrocyte transitions or defects in osteoblast lineage development (c). Overall, the skeletal characterization is not rigorous and does not identify even a likely cellular mechanism. Further, a molecular mechanism by which SMN functions in mesenchymal progenitors, chondrocytes, or osteoblast lineage cells has not been assessed (d).</p></disp-quote><p>(a, c) As the reviewer commented, it seems to be a very important point to evaluate whether there is any problem in embryonic development from the time of mesenchymal cell condensation of the limb bud to the primary ossification center. However, when Hensel et al evaluated bone growth in P3 of severe SMA mice, the growth defect was not very large, with control femur length 3.5 mm and mutant 3.2 mm. it seems that even if SMN defects occur, there is no major problem with endochondral bone formation in the embryonic period (Hensel et al., 2020).</p><p>In this study, the SMN2 1-copy mutant with the bone growth defect was found to have a similar reduction in SMN protein to the severe SMA mouse model in experiments quantifying SMN protein. When Hensel et al. performed an in vitro ossification test on primary osteoblasts from the other severe SMA mouse model (Taiwanese severe SMA), they found no significant difference compared to controls. In femurs at P3 from severe SMA mice, they found no difference in bone voxel density and bone thickness (Hensel et al., 2020). In our data, bone thickness was not different in Figure 1 and Figure 1 – figure supplement 2, and BMD was actually greater. Thus, we believe that osteoblast and osteocyte function does not appear to be impaired by the absence of SMNs. When we looked at cortical osteoblasts in our new Figure 1-figure supplement 2, there did not appear to be a significant difference in density.</p><p>Furthermore, it is unlikely that BMSCs contributed to the bone growth we observed up to 2 weeks of age. the Lepr+Cxcl12+ BMSC population, which constitutes 94% ± 4% of CFU-F colonies formed by bone marrow cells (Zhou et al.k, 2014), is Prrx1-positive, and is known to be capable of osteogenesis in vivo, was only shown to differentiate into osteoblasts and form new bone in adults over 8 weeks of age. In the Lepr-cre; tdTomato; Col2.3-GFP mouse model, few cells expressing the osteoblast marker Col2.3-GFP are found before 2 months, and only about 3% of femur trabecular and cortical osteocytes express tdTomato at 2 months (Zhou et al., 2014). In Cxcl12-CreER; tdTomato; Col2.3-GFP mouse model, the researchers did not find tomato positivity in osteoblasts and osteocytes even after administration of tamoxifen at P3 and analysis 1 year later (Matsushita et al., 2020).</p><p>We, therefore, concluded that the bone growth abnormalities observed in SMN2 1-copy mutants are due to problems in endochondral ossification caused by chondrocyte defects and not due to other Prrx1-lineage skeletal cells.</p><p>(b) According to the reviewer's suggestion, we evaluated cell proliferation in the new Figure 1J-L by performing immunostaining for the Ki67 proliferation marker in growth plates.</p><p>(d) As the reviewer pointed out, we enhanced the mechanism study and found the reduction of chondrocyte-derived IGF signaling and hypertrophic marker in new Figure 2. We evaluated the density of osteoblasts and osteoclasts, which can affect bone mineralization. We highlighted the limited impact of BMSCs on bone growth in the first two weeks of life. In a previous study, SMN-deleted osteoblasts did not show any issues with ossification (Hensel et al., 2020). In fact, osteoblast density in the SMN2 1-copy mutant was not different from the control, indicating that the skeletal abnormalities can largely be attributed to deficiencies in endochondral ossification caused by chondrocytes. Since chondrocytes are the local source of IGF and our mutants exhibit phenotypes similar to mouse models with reduced IGF, such as downregulated expression of Igf1 and Igfbp3, downregulated IGF-induced hypertrophic gene expression, reduced AKT phosphorylation, proliferation, and growth plate zone length, SMN-deleted chondrocytes probably showed these phenotypes due to decreased IGF secretion. Now, we added new Figure 2A-C, and E.</p><disp-quote content-type="editor-comment"><p>1. Is the liver the only organ/tissue that supplied IGF to the chondrocytes or are other lateral plate mesoderm-derived cells potential suppliers? It's not possible to pin SMN deletion in chondrocytes as intrinsic ignoring the other bone cell types that it is depleted from in the Prrx1Cre genetic model.</p></disp-quote><p>Recently, Oichi et al. reported that the local IGF source in the growth plate is chondrocytes by in situ hybridization and p-AKT staining (Oichi et al., 2023). When we measured IGF in chondrocytes isolated from articular cartilage, the expressions of Igf1 andIgfbp3 were markedly reduced in chondrocytes with SMN deletion compared to controls (New Figure 2E), suggesting that intrinsic SMN expression in chondrocytes plays an important role in the growth plate.</p><disp-quote content-type="editor-comment"><p>1. Why is SMN protein being isolated from FAPs to assess levels in the null/SMN2 single copy/double copy mutants when the bone defects are supposed to be a chondrocyte-specific phenotype? This protein expression needs to be confirmed in chondrocytes themselves, and or other Prrx1Cre lineaged skeletal cells.</p></disp-quote><p>According to the reviewer’s suggestion, we attempted to evaluate the protein levels in chondrocytes of the SMN2 1-copy mutant. However, we were unable to obtain sufficient numbers of chondrocytes, because of poor proliferation of mutant chondrocytes compared to controls in culture conditions. We could obtain ~10^4 viable cells from 1 mouse of SMN2 1-copy mutant. Therefore, our only options for confirming SMN deletion in chondrocytes were DNA and RNA work. As in the Prrx1-lineage FAPs that the amount of SMN protein correlates with the expression levels of full-length SMN mRNA (Figure 2H-J), we expect that the SMN protein in chondrocytes would be fully depleted due to poor full-length SMN mRNA expression (Figure 2H).</p><disp-quote content-type="editor-comment"><p>1. Figure 2E should have example images of each type of NMJ characterization.</p></disp-quote><p>We revised our figure by adding the example images in new Figure 3E.</p><disp-quote content-type="editor-comment"><p>1. What are the overall NMJ numbers in the normal formation period? Are these constant into the juvenile period when the authors say the deterioration occurs?</p></disp-quote><p>We appreciate the reviewer's constructive comments, and it would be interesting to see if we could see a difference in the total number of NMJs. However, there is one NMJ in every myofiber, and each muscle has hundreds to thousands of myofibers. The technical difficulty of confocal imaging an entire muscle, which can be several millimeters across, precludes experiments that count every NMJ and show a difference. It may be possible to do so by combining clearing and confocal line scanning techniques. In our analysis of the NMJ, the formation of the NMJ in the mutant appears to be normal. Additionally, the number of myofibers seems to be the same, and there may be no difference in the total NMJ number.</p><disp-quote content-type="editor-comment"><p>1. For transplantation experiments the authors sorted YFP or TOMATO+ cells from the Prrx1Cre mice muscles, but refer to them as FAPs. It is known that other cells including tenocyte-like cells, pericytes, and vascular smooth muscle cells are identified by this reporter line. Staining for TOMATO colocalization with PDGFRA would help to clarify this.</p></disp-quote><p>In the method ‘Hindlimb fibro-adipogenic progenitors isolation’ section, we sorted 7AAD–Lin–Vcam–Sca1+ population refers to FAPs. For FAPs transplantation, we also used YFP or TOMATO+ FAPs (7AAD–Lin–Vcam–Sca1+). The ‘FAPs transplantation’ method section did not specify the FAPs population in detail. This has been fixed in the new method. Sca1 (Ly6a) is an effective marker for identifying FAPs within Prrx1-lineage cells, as well as Pdgfra (Leinroth et al., 2022).</p><disp-quote content-type="editor-comment"><p>1. The authors only compare the SMN2 single copy mutant transplantation to contralateral to show rescue, but how does this compare to overall wt morphology?</p></disp-quote><p>According to the reviewer’s constructive comment, we compared them with wild-type morphology (new Figure 7A-D).</p><disp-quote content-type="editor-comment"><p>1. The asterisks of TOMATO+ in Figure 6A are confusing. FAPs do not usually clump together to form such large plaques and are normally much thinner tendrils. What is the reason for this?</p></disp-quote><p>As the reviewer states, FAPs have a fibroblast-like morphology with elongated thinner tendrils. The Figure 6A image in the figure shows a Z-sliced cell body portion of FAP, where the nucleus is located, and it appears blunt. We attached imaged tomato+ FAPs, in which their cell body parts are plaque-like.</p><fig id="sa4fig1" position="float"><label>Author response image 1.</label><caption><title>Tomato+ FAPs in muscle.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92731-sa4-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>1. Would transplantation of healthy FAPs after NMJ maturation in SMN mutants still rescue the phenotype? Assessment of this is key for therapy intervention timelines moving forward.</p></disp-quote><p>It will be very interesting to see if the phenotype improves after NMJ maturation by healthy FAPs transplantation, but this is a technically difficult experiment to do because we found that FAPs do not implant effectively when injected into naive adult muscle. The transplantation into the adult is sufficiently possible if accompanied by an injury, but this eventually leads to new formation of NMJ again. Thus, it seems impossible to do transplantation experiment after NMJ maturation through general methods. If we discover a method to efficiently rescue SMNs from FAPs or identify a factor that affects FAPs' influence on NMJ, then we may be able to conduct this experiment.</p><p>Reference</p><p>Hensel, N., Brickwedde, H., Tsaknakis, K., Grages, A., Braunschweig, L., Lüders, K. A., Lorenz, H. M., Lippross, S., Walter, L. M., Tavassol, F., Lienenklaus, S., Neunaber, C., Claus, P., &amp; Hell, A. K. (2020). Altered bone development with impaired cartilage formation precedes neuromuscular symptoms in spinal muscular atrophy. Human Molecular Genetics, 29(16), 2662–2673. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/hmg/ddaa145">https://doi.org/10.1093/hmg/ddaa145</ext-link></p><p>Leinroth, A. P., Mirando, A. J., Rouse, D., Kobayahsi, Y., Tata, P. R., Rueckert, H. E., Liao, Y., Long, J. T., Chakkalakal, J. V., &amp; Hilton, M. J. (2022). Identification of distinct non-myogenic skeletal-muscle-resident mesenchymal cell populations. Cell Reports, 39(6), 110785. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.celrep.2022.110785">https://doi.org/10.1016/j.celrep.2022.110785</ext-link></p><p>Matsushita, Y., Nagata, M., Kozloff, K. M., Welch, J. D., Mizuhashi, K., Tokavanich, N., Hallett, S. A., Link, D. C., Nagasawa, T., Ono, W., &amp; Ono, N. (2020). A Wnt-mediated transformation of the bone marrow stromal cell identity orchestrates skeletal regeneration. Nature Communications, 11(1). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-019-14029-w">https://doi.org/10.1038/s41467-019-14029-w</ext-link></p><p>Oichi, T., Kodama, J., Wilson, K., Tian, H., Imamura Kawasawa, Y., Usami, Y., Oshima, Y., Saito, T., Tanaka, S., Iwamoto, M., Otsuru, S., &amp; Enomoto-Iwamoto, M. (2023). Nutrient-regulated dynamics of chondroprogenitors in the postnatal murine growth plate. Bone Research, 11(1). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41413-023-00258-9">https://doi.org/10.1038/s41413-023-00258-9</ext-link></p><p>Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G., &amp; Morrison, S. J. (2014). Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell, 15(2), 154–168. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.stem.2014.06.008">https://doi.org/10.1016/j.stem.2014.06.008</ext-link></p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2</bold></p><p>Major comments:</p><p>1. Regarding bone deficits - CT analysis of bones should be more comprehensive than Figure 1A shows. How about cross-sections? (a) Are bone phenotypes also age-dependent? (b) PCR was done only for SMA and related proteins (such as IGF). IGF protein in the blood and relevant organs should be studied. Why not include biomarkers of osteoblasts or/and osteoclasts and their regulators? (c)</p></disp-quote><p>(a) We appreciate the reviewer’s constructive comment. we added longitudinal section views in new Figure 1A and a description of trabecular bone volume and secondary ossification center in the main text.</p><p>(b) Age-dependent evaluation is an important point. By adulthood, the difference between the SMN2 1-copy mutant and the control is much larger, and even at birth there is a slight difference, although not as large as at 2 weeks of age. We focused our phenotyping on bone growth at 2 weeks of age, a time when new bone formation by BMSCs is less influential, when bone growth is primarily driven by endochondral ossification of chondrocytes, and before the defect in theNMJ is primarily manifested.</p><p>(c) As the reviewer comments, it is important that IGF are evaluated in tissues other than liver. However, the liver is most likely the source of systemic IGF, as shown by the liver-specific deletion of Igf1 and knockout of Igfals, a protein that forms the IGF ternary complex, which is predominantly expressed in the liver. This resulted in a 90% drop in serum IGF levels and a phenotype of shortened femur length and growth plates in the double KO mice (Yakar et al., 2002).</p><p>The local IGF source in the growth plate is chondrocytes confirmed by Igf1 in situ hybridization and p-AKT staining (Oichi et al., 2023). From the In situ hybridization data, we can observe that bone marrow and bone do not express Igf1 at all, but only perichondrium and chondrocytes in the resting zone express Igf1 mRNA. Therefore, we can see that the only supplier of IGF among LPM-derived cells is chondrocytes, and in the new figure 2, we measured IGF pathway expression and AKT phosphorylation in chondrocytes. We have confirmed that the expression of Igf1/Igfbp3 is reduced in chondrocytes with SMN deletion.</p><p>To assess serum IGF level, we could not set up this experiment condition during our revision period due to the requirement of administrative procedures for purchasing new apparatuses and the limitation of our research funds. However, as previously stated, there is no difference in the expression of Igf1 and Igfals in the liver, which accounts for 90% of serum IGF levels. Therefore, we did not anticipate significant variations in serum IGF levels.</p><p>Evaluation of osteoblasts or osteoclasts was done by section staining due to sampling difficulties for PCR. we assessed osteoblasts and osteoclasts state in new Figure 1-figure supplement 2.</p><disp-quote content-type="editor-comment"><p>1. What is the relationship between deficits of bone deficits and muscle deficits or even NMJ deficits? Are they inter-related? Is skeletal muscle development also defective in Smn∆MPC mice? Can NMJ deficits result from bone deficits? Or vice versa?</p></disp-quote><p>Unfortunately, the reviewer's comments are very difficult to clarify in our study using the Prrx1-cre model. In skeletal muscle development, the myofiber number was not significantly different in our mouse models. A study has shown that inactivating noggin, a BMP antagonist expressed in condensed cartilage and immature chondrocytes, results in severe skeletal defects without affecting the early stages of muscle differentiation (Tylzanowski et al., 2006). Therefore, bone may not have a significant impact on the early development of muscle, but later in postnatal development it may have an impact on motor performance issues. The relationship between bone and NMJ hasn't been studied. The impact of bone defects on motor skill may result in muscle weakness and NMJ problems. In our study, we showed that NMJ deficit rescue by transplantation of FAPs and decreased IGF in chondrocytes, a key source of local IGF. This suggests that the functions of FAPs in NMJ and chondrocytes in bone deficit are crucial, rather than each other's influence.</p><disp-quote content-type="editor-comment"><p>1. Regarding the rescue experiment, the interpretation of the data should be careful. Evidently, healthy FAPs (td-Tomato positive) were transplanted into TA muscles of 10 days-old SMN2 1-copy SmnΔMPC mice, and NMJs were looked at P56. The control was contralateral TA that was injected with the vehicle. As described above, the data had huge SEM and were difficult to interpret or believe. The control perhaps was wrong if FAPs act by releasing &quot;chemicals&quot; because FAPs from one leg may go to other muscles via blood. Second, if FAPs act via contact, the data shown did not support this. Two red FAPs were shown in Figure 6, one of which was superimposed with a nerve track to one of the three NMJs. This NMJ however did not show any difference to the other two, which did not support a contact mechanism. These rescue data were not convincing.</p></disp-quote><p>We appreciate the reviewer’s critical comment, but the reviewer appears to have confused the minimum and maximum range bars in the box-and-whisker plot with the SEM error bar in the bar graph. We apologize for the insufficient description of the figure legends section. We revised them. New Figure 7C, which is a bar graph, has a sufficiently short SEM error bar. In contrast, box-and-whisker plots B and D depict the minimum and maximum range, instead of the SEM, and they are significantly different with a p-value of less than 0.001. If FAPs affect the NMJ via a paracrine factor or ECM with a short range of action, they may rescue the NMJ defect in a non-contact-dependent manner, without affecting the contralateral muscle. Also, the FAPs are heterogeneous, so if only a certain subpopulation rescues, the tomato+ FAP in the figure may not be the rescuing cells.</p><disp-quote content-type="editor-comment"><p>1. For most experiments, the &quot;n&quot; numbers were too small. 3-5 mice were used for bone characterization. For the NMJ, most experiments were done with 3 mice. It was unclear how many NMJs were looked at. Perhaps due to small n numbers, the SEM values were enormous (for example, in Figure 6).</p></disp-quote><p>As with the response to the previous comment, this is due to confusion between box-and-whisker plots and bar graphs, and our data was determined to be significant using the appropriate statistical method.</p><disp-quote content-type="editor-comment"><p>1. Also for experimental design, some experiments included four genotypes of mice (Fig. 1 J,K) whereas some had only three (Fig.1 A, B, C, D and Fig.3) and others had two (many other figures).</p></disp-quote><p>In the first experiments to confirm the phenotypes, we tested the 2-copy mutant, but it was not significantly different from the wild type, and in subsequent experiments, we mainly tested the only 1-copy mutant.</p><disp-quote content-type="editor-comment"><p>1. What was the reason why mixed muscles were used for NMJ characterization (TA versus EDL)? Why not pick a type I-fiber muscle and a type II-fiber muscle?</p></disp-quote><p>We appreciate the constructive comment from the reviewer. Firstly, we conducted a phenotype analysis on the TA muscle. For electrophysiological recording, the EDL muscle should be used for intact nerve with muscle preparation, technically. Additionally, for TEM imaging, EDL was a suitable muscle to locate NMJ positions before TEM processing. Both TA and EDL muscles are adjacent and have similar fiber-type compositions. It would be important to observe in different fiber types of muscles, but when we first identified the phenotype, various types of limb muscles showed similar defects, so we focused on specific muscles.</p><disp-quote content-type="editor-comment"><p>1. The description of mouse strains was confusing. SMN2 transgenic mice (with different copies) were not described in the methods.</p></disp-quote><p>We apologize for the insufficient description of the method section. By crossing mice with the SMN2+/+ homologous allele, SMN2 heterologous mice with only one SMN2 allele are SMN2 1-copy mice (SMN2+/0) and SMN2 homologous mice are SMN2 2-copy mice (SMN2+/+). We revised our manuscript method ‘Animals’ section.</p><p>ReferenceOichi, T., Kodama, J., Wilson, K., Tian, H., Imamura Kawasawa, Y., Usami, Y., Oshima, Y., Saito, T., Tanaka, S., Iwamoto, M., Otsuru, S., &amp; Enomoto-Iwamoto, M. (2023). Nutrient-regulated dynamics of chondroprogenitors in the postnatal murine growth plate. Bone Research, 11(1). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41413-023-00258-9">https://doi.org/10.1038/s41413-023-00258-9</ext-link></p><p>Tylzanowski, P., Mebis, L., and Luyten, F. P. (2006). The noggin null mouse phenotype is strain dependent and haploinsufficiency leads to skeletal defects. Dev. Dyn. 235, 1599–1607. doi: 10.1002/dvdy.20782</p><p>Yakar, S., Rosen, C. J., Beamer, W. G., Ackert-Bicknell, C. L., Wu, Y., Liu, J. L., Ooi, G. T., Setser, J., Frystyk, J., Boisclair, Y. R., &amp; LeRoith, D. (2002). Circulating levels of IGF-1 directly regulate bone growth and density. Journal of Clinical Investigation, 110(6), 771–781. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI0215463">https://doi.org/10.1172/JCI0215463</ext-link></p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3</bold></p><p>1. The authors used Prrx1Cre mouse with floxed Smn exon7(Smnf7) mouse carrying multiple (one or two) copies of the human SMN2 gene. Is it expressed both in chondrocytes and mesenchymal progenitors in the limb?</p></disp-quote><p>We appreciate the reviewer's comment. We analyzed the deletion of Smn in chondrocytes and FAPs via Cre using genomic PCR and qRT-PCR, as depicted in new Figure 2. The SMN2 allele, which is expressed throughout the body, can rescue Smn knockout mouse lethality (Monani et al., 2000). Indeed, the short limb length and lethality observed in SMN2 0-copy mutants were mitigated by the presence of multiple copies of SMN2. Therefore, both Chondrocytes and FAPs may express SMN2 transcripts from the transgenic SMN2 allele.</p><disp-quote content-type="editor-comment"><p>1. Page 10 regarding Fig.2E, please show pretzel-like structure. In Figure 2E, plaque, perforated, open, and branched are shown; however, the pretzel is not shown. The same issue is for the Fig. 3D explanation in the text on page 12.</p></disp-quote><p>We appreciate the reviewer's constructive feedback. We included illustrative figures of all types of NMJ characterization, and the branched type is identical to the pretzel type. Therefore, we have replaced ‘branched’ with ‘pretzel’ in our text and revised Figure 3E by incorporating the example images.</p><disp-quote content-type="editor-comment"><p>1. The explanation of the electrophysiology for Fig.4 in the text on pages 12 and 15 (RRP) is not so convincing for the readers. It is advisable to add TEM data for transplantation if it is not technically difficult.</p></disp-quote><p>We appreciate the reviewer's critical feedback. Because we did not measure RRP directly, we removed speculation about the possibility of RRP difference. If observing the active zone with TEM and the docking synaptic vesicle would help quantify RRP, it is technically difficult to obtain images of sufficient quality to distinguish the active zones with our current TEM imaging technique.</p><disp-quote content-type="editor-comment"><p>1. The authors used the word FAP for 7AAD(-)Lin(-)Vcam(-)Sca1(+). It is recommended to show the expression of PDGFR alpha. Furthermore, as the authors stated in the text, mesenchymal progenitors (FAPs) are heterogeneous. Please discuss this point further. Other reports show at least 6 subpopulations using single-cell analyses (Cell Rep. 2022).</p></disp-quote><p>In the report, Ly6a (Sca1) is a good marker for FAPs, as well as Pdgfra (Leinroth et al., 2022). The 6 subpopulations expressed Ly6a. The one of subpopulations associated with NMJ was discovered. This population expressed Hsd11b1, Gfra1, and Ret and is located adjacent to the NMJ and responds to denervation, indicating an increased possibility of interaction with the NMJ organization. In further our study, we aim to determine which subpopulations are crucial for NMJ maturation by transplanting them to mutants for rescue.</p><disp-quote content-type="editor-comment"><p>1. How do authors determine the number of FAP cells for transplantation?</p></disp-quote><p>The FAPs transplantation was performed according to a previously reported our study (Kim et al., 2021).</p><p>ReferenceKim, J. H., Kang, J. S., Yoo, K., Jeong, J., Park, I., Park, J. H., Rhee, J., Jeon, S., Jo, Y. W., Hann, S. H., Seo, M., Moon, S., Um, S. J., Seong, R. H., &amp; Kong, Y. Y. (2022). Bap1/SMN axis in Dpp4+ skeletal muscle mesenchymal cells regulates the neuromuscular system. JCI Insight, 7(10). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/jci.insight.158380">https://doi.org/10.1172/jci.insight.158380</ext-link></p><p>Leinroth, A. P., Mirando, A. J., Rouse, D., Kobayahsi, Y., Tata, P. R., Rueckert, H. E., Liao, Y., Long, J. T., Chakkalakal, J. V., &amp; Hilton, M. J. (2022). Identification of distinct non-myogenic skeletal-muscle-resident mesenchymal cell populations. Cell Reports, 39(6), 110785. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.celrep.2022.110785">https://doi.org/10.1016/j.celrep.2022.110785</ext-link></p><p>Monani, U. R., Sendtner, M., Coovert, D. D., Parsons, D. W., Andreassi, C., Le, T. T., Jablonka, S., Schrank, B., Rossol, W., Prior, T. W., Morris, G. E., &amp; Burghes, A. H. M. (2000). The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Human Molecular Genetics, 9(3), 333–339. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/hmg/9.3.333">https://doi.org/10.1093/hmg/9.3.333</ext-link></p></body></sub-article></article>